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A. Abstract 
In this work, the dependence of transdermal delivery of hydrophilic drugs on mass fraction and 
microstructure of dispersed phase of multi-phase dermatological o/w formulations was studied. 
Permeation of sodium nicotinate, caffeine and benzyltrimethylammonium chloride (BTA-Cl), 
used as model drugs, was studied under occlusive conditions. Sodium nicotinate permeation 
was also investigated non-occlusively taking especially into consideration alterations these 
formulations may undergo due to evaporation of volatile components. The study formulations 
included a typical emulsion (E) consisting of triglycerides, emulsifier (polysorbate 20) aqueous 
buffer pH 7.4 and ethanol, a typical liposomal dispersion (LD) consisting of phospholipids, 
aqueous buffer pH 7.4 and ethanol and two complex formulations, CF10 and CF50, each 
consisting of all these components. These formulations were designed in order to consider not 
only diversity in their composition but also widely varying ratios of dispersed to continuous 
phase. CF50 and E contained a high amount of dispersed phase of 50 weight-% and LD and 
CF10 a comparatively low amount of dispersed phase of 10 weight-%. Permeation was studied 
in-vitro using Franz-type diffusion cells across excised full-thickness pig ear skin. A concept is 
proposed for the interpretation of the permeation data. This concept postulates that continuous 
phase drug concentration of the formulations is the only parameter governing permeation 
kinetics. As reference, purely aqueous or aqueous/ethanolic gel formulations were used. 
Coexisting dispersed structures of the formulations were fractionated using ultracentrifugation. 
The received fractions of all formulations were characterised by chemical component analysis, 
scanning electron microscopy and particle size measurements. Emulsion droplets were 
creaming and liposomes sedimenting, as attested by formulation E and LD, respectively. CF50 
comprised emulsion droplets and a microemulsion that consisted of 13 weight-% 
phospholipids, 13 weight-% triglycerides, 10 weight-% polysorbate 20 and of 64 weight-% 
hydrophilic phase. NMR-diffusion measurements demonstrated a droplet-like o/w structure for 
this system. Particle size measurements following different dilution steps indicated a stable 
droplet size of 20-24 nm. No liposomal structures were detected within CF50. For CF10, a 
coexistence of liposomes, emulsion droplets and small quantity of microemulsion aggregates 
was found. The continuous phase of all formulations consisted of aqueous buffer and the total 
amount of ethanol, independently of dispersed structures. Distribution of the drugs between 
distinct phases of the formulations was studied using the shake-flask method and ultrafiltration. 
Sodium nicotinate and BTA-Cl distributed completely into the hydrophilic phase of the 
formulations, according to their solubility properties, while caffeine showed moderate 
distribution into triglycerides. Based on these observations, continuous phase drug 
concentrations were calculated.  
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Caffeine permeation from the formulations across a silicon membrane gave equal permeability 
coefficients, calculated with continuous phase drug concentration, clearly demonstrating the 
validity of the proposed concept. Permeability coefficients across skin, however, were different, 
depending on the formulation. The same was true also for BTA-Cl and sodium nicotinate. This 
was not due to variable molecular mobility of drug within the formulations, as attested with 
sodium nicotinate NMR diffusion experiments. The possible effect of formulations on the 
barrier function of the skin was investigated by measuring distribution of drugs between the 
stratum corneum and continuous phase of the formulations and calculating the diffusion 
coefficients within the stratum corneum. This demonstrated clearly that CF10 and CF50 were 
able to increase drug diffusion coefficients within the stratum corneum statistical significantly 
for all model drugs. Furthermore, a reduction of drug distribution between stratum corneum 
and formulation with increasing amount of dispersed phase of all formulations was observed 
which was responsible for retardation of skin permeation. Drug permeation was ultimately the 
combined result of these two contrasting formulation effects on skin barrier function. The 
diffusion enhancing effect of CF10 and CF50 was shown to be due to the microemulsions 
contained in these formulations. The presence of ethanol was found to be essential for this 
effect, demonstrating a synergism of the microemulsions with the ethanol.  
During evaporation of volatile formulation compounds, several phase transitions were 
detected, such as: vesicle to microemulsion in case of CF10, phase inversion from o/w to w/o 
in case of CF50 and drug precipitation due to exceeded maximum solubility in case of E. For 
LD and CF10, sodium nicotinate fluxes were continuously increasing in course of the 
permeation experiments. The emulsion yielded a constant flux, while the phase inversion 
observed in case of CF50 very likely caused a decrease in permeation. For quantitative 
interpretation of the permeation data, the continuous phase drug concentration concept was 
expanded to the situation of non-occlusive application. The increase of permeability for non-
occlusively applied formulations was up to tenfold, compared to an occlusively applied purely 
aqueous gel. This could be explained by the resulting continuous phase drug concentrations, 
independently of arising microstructures. Hence, this concentration governed sodium 
nicotinate permeation in this situation alone, without the need to consider formulation effects 
on skin barrier function. This is in good agreement with the observed synergism of the ethanol 
with the microemulsions, because ethanol evaporated very quickly from the formulations 
following non-occlusive application. 
To conclude, taking into account continuous phase drug concentration of multi-phase 
formulations provides a predictive tool in order to delineate the effect of physicochemical 
formulation parameters and of formulation effects on skin barrier function on delivery rate. This 
is true for occlusive and non-occlusive application. 
  
Introduction and Objectives 
   
 
3 
 
B. Introduction and Objectives 
In clinical practice, drugs are normally incorporated in a vehicle in order to be applied to the 
skin for topical or systemic therapy (1). Vehicles typically consist of several components that 
are often not mutually miscible, thus forming separate phases. The phases of such 
dermatological formulations are intermixed, producing macroscopically homogeneous 
systems. On the microscopic level, however, these phases form different structures, which 
may be identified using a combination of methods including microscopy, rheology 
measurements, ultracentrifugation and NMR spectroscopy (2,3,4,5). 
Dermatological formulations are developed and optimised with respect to a host of criteria 
such as applicability, tolerability, stability and foremostly efficacy, which comprises duration 
and strength of pharmacological action. This regulation may take place based on 
physicochemical principles or by an interaction of formulation structures with the absorptive 
epithelium, i.e., the epidermis, affecting its permeability of the drug. In all likelihood, the 
available drug concentration in the vehicle is the most crucial physicochemical parameter 
governing permeation kinetics (6), as already demonstrated by Coldman et al. in 1969, who 
investigated fluocinolone acetonide penetration from different solutions (7). Microemulsions 
(8,9,10,11) and liposomal vesicles (12,13,14,15) represent classes of multi-phase vehicles 
which may further affect skin permeation by reducing the transport barrier function of the 
stratum corneum. For such formulations, however, drug distribution among distinct phases 
may have additional impact on delivery rate by adjusting the portion of drug that is available for 
permeation. Hummel and Imanidis showed that ibuprofen distributed strongly into lipophilic 
dispersed phase structures of multi-phase o/w formulations and the resulting continuous phase 
drug concentration explained quantitatively permeation kinetics across pig-ear skin in-vitro (4). 
Thus, for multi-phase formulations, this concentration seems to be an essential parameter to 
interpret drug skin permeation and, consequently, to identify possible formulation effects on 
skin barrier function.  
Moreover, dermatological formulations are typically applied to the skin as a thin layer under 
non-occlusive conditions and are intended to deliver the active ingredient for hours. After 
application, however, the composition of the formulation may change, commonly because of 
evaporation of volatile components (1,4). Such a change in the composition of a multi-phase 
system likely elicits alterations of the phase structure of the system and of the concentration 
and distribution of the active ingredient in it. These alterations in turn can affect delivery 
performance. This aspect, however, was studied mostly with volatile solutions (7,16) or was 
not always related to its effect on drug permeation (17,18). 
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Consequently, a variety of factors combine to complicate a correct interpretation of how drug 
transport across the skin depends on the delivery formulation. Despite the efforts made to date 
to elucidate the influence of the formulation on skin absorption on a mechanistic basis, there is 
still no unifying theory that allows safe prediction of the process (19). Important aspects, such 
as drug distribution among distinct phases and alterations of the formulation following 
application are commonly considered empirically, and intuition as well as trial and error often 
surrogate for science in dermatological formulation development and in clinical practice (1). 
Thus, there is big need for a general theory that takes into account physicochemical 
formulation parameters and may be applied to occlusive and non-occlusive delivery conditions 
in order to test drug skin permeation in-vitro. For this purpose, methodological aspects should 
further be considered (20). Such a concept would make a valuable contribution to clinical drug 
delivery and, importantly, to an effective development of dermatological formulations.  
Objectives 
The purpose of this PhD thesis was to establish a methodology to understand quantitatively 
the dependence of transdermal drug permeation on microstructure and mass fraction of 
dispersed phase of multi-phasic dermatological o/w formulations and on changes these 
parameters may undergo following non-occlusive application. Drug permeation was studied in 
vitro across full-thickness pig ear skin to control the experimental environment and so to 
elucidate individual factors that may modify permeation. Representative o/w formulations, 
consisting of emulsifier, triglycerides, phospholipids, buffer and ethanol, were designed in 
order to receive diversity of their composition and variety of their phase ratio of dispersed to 
continuous phase. Different coexisting microstructures were separated using 
ultracentrifugation and characterised by physicochemical methods. Drug distribution was 
determined with respect to the microstructure and to mass fraction of dispersed phases of the 
formulations to calculate continuous phase drug concentrations. This concentration was 
postulated to describe quantitatively drug permeation rate. The use of hydrophilic model drugs 
which distribute strongly into the hydrophilic phase of formulations was the basis to test this 
concept and to detect possible interactions of dispersed formulation structures with the skin. 
To delineate the effect of formulation structures on skin barrier function more detailed, drug 
distribution experiments between isolated stratum corneum and formulations were performed 
and drug diffusion coefficients within stratum corneum were calculated. With respect to clinical 
practice, permeation was further studied non-occlusively considering changes the formulations 
undergo due to evaporation of volatile components. Emphasis was laid on the investigation of 
different phase transitions and on changes of the phase ratios from dispersed to continuous 
phases in order to expand the continuous phase drug concentration concept to the situation of 
non-occlusive application. 
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C Theoretical Section 
C.1 The Skin 
The skin has the primary function to provide a barrier against environmental influences (21) 
and to protect the body against the loss of endogenous substances (22). Furthermore, the skin 
is also a major contributor to thermoregulation and performs endocrine functions, e.g. Vitamin 
D synthesis or peripheral conversion of prohormones (23). Macroscopically, two distinct skin 
layers are apparent, an unvascularized outer layer (epidermis) and an inner vascularized layer. 
The vascularized layer consists of the dermis and the hypodermis and has the function to 
provide physiological support to the unvascularized epidermis. This layer comprises the viable 
epidermis and the outermost layer of the skin, the stratum corneum, which consists of dead 
keratin-filled cells. Fig.1 gives an overview about the dimensions and the stratified appearance 
of the skin. 
 
 
Figure 1 Skin tissue layers. From Schaefer and Redelmaier, 1993 (21) 
 
C.1.1 The Viable Epidermis and Epidermal Differentiation 
The viable epidermis is divisible into three distinct layers, namely, from inside to outside: 
Stratum basale, statum spinosum and the stratum granulosum. The cells of these layers 
undergo continuous differentation to produce the outermost layer of the skin, the stratum 
corneum, that consists of layers of dead keratin filled cells. Due to this process, histological 
preparations of the epidermis are of stratified appearance.  
Theoretical Section 
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The stratum basale is a single layer of epidermal stem cells which are anchored to a basement 
membrane that separates the epidermal tissue from the underlying dermis. The basal cells are 
continually dividing, creating cells that undergo several changes while moving towards the skin 
surface in further course of differentiation. Above, these differentiating cells are forming the 
stratum spinosum. The cells are now of spiny appearance, due to abundance of desmosomes. 
In addition to the cell organelles seen in the basal layer, the stratum spinosum also reveals 
lipid enriched lamellar bodies (also called Odland bodies) and an increase in keratin filaments, 
indicating the dual character of the differentiation, protein and lipid synthesis (23). On their way 
to the skin surface, the cells begin to flatten and elongate, forming the stratum granulosum. 
Distinct keratohyalin granules that become larger in the upper granulocytes reflect an increase 
in keratin synthesis, accompanied by an increasing number of lamellar bodies. In course of the 
terminal differentiation of the uppermost granulocytes into a corneocyte, these lamellar bodies 
are secreted to the extracellular domains, forming the stratum corneum extracellular bilayers. 
This process is accompanied by the formation of the corneocyte`s cornified envelope, the 
dissolution of cell organelles and the condensation of the enriched keratin filaments. The 
nature of the signals that initiate the irreversible process of cornification is still elucidated, but it 
is evidenced that an extracellular calcium gradient with higher Ca2+ concentrations in the upper 
regions of the viable epidermis triggers the transformation from a granulozyte to a corneozyte. 
The deceased cells are finally shed from the skin by desquamation. The complete renewing 
process takes about 3-4 weeks. The viable part of the epidermis also contains melanocytes 
that are responsible for skin pigmentation, antigen presenting Langerhans cells and Merkel 
cells (mechanoreceptors) (24). 
 
C.1.2 The Stratum Corneum 
The stratum corneum constitutes the outermost layer of the epidermis and represents the main 
barrier function, although it is the thinnest and smallest compartment of the skin. It is about 10 
to 20 µm thick and consists of several layers of dead, keratin filled corneocytes that represent 
the final state of epidermal differentiation (see C.1.1). These cells are embedded in a matrix of 
lipid lamellas that descend from the secreted content of the lamellar bodies, which gives the 
stratum corneum a brick and mortar organisation (23). A rigid envelope that replaces the 
plasma membrane surrounds the corneocytes after terminal differentiation. This cornified 
envelope in turn is coated with long chain ceramides, some of them covalently attached 
through ester linkages to the outer surface of the envelope. A free interaction of their acid 
chains with unbound extracellular lipid lamellae assists establishing the lamellar organisation in 
the extracellular lipids (25). Another speciality of the stratum corneum is the lipid composition, 
which differs significantly from those of the cells of the lower epidermal layers. The lipid 
composition of the stratum basale is comparable with that of cells of other tissues and 
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constitutes mainly of phospholipids. In the stratum granulosum, a drastically decrease in the 
phospholipids occur for the benefit of sphingolipids and cholesterol. The extracellular lipid 
matrix of the stratum corneum finally is free of phospholipids and consists of ceramids, 
cholesterol and free fatty acids in roughly equimolar ratios (23). The ceramides are crucial for 
the lipid organisation of the stratum corneum barrier, while the cholesterol is promoting the 
intermixing of different lipid species. Fig.2 points out these differences in lipid composition for 
the stratum basale, the stratum granulosum and the stratum corneum.  
 
 
Figure 2 Lipid composition of different epidermal layers. From Schaefer and Redelmaier, 1993 (21) 
 
Water-holding properties of the stratum corneum are influenced by the rate of proteolysis, 
which generates a blend of amino acids termed as natural moisturing factors (26). The general 
degree of hydration of the stratum corneum is between 10 to 30% bound water, depending on 
the location within the stratum corneum, body site and environmental conditions. Under 
occlusive conditions (defined as complete impairment of passive transepidermal water loss, 
see also C.4.2.1), however, the stratum corneum may bind a 2.75 fold amount of water 
compared to its dry weight (27). 
C.1.3 The Dermis and the Hypodermis 
The dermis is connected by the basement membrane to the stratum basale. This junction is of 
folded appearance, supporting the exchange of nutrients and other physiological substances 
with the unvascularized epidermis. Main components of the dermis are collagen and elastin 
fibres that form a vast network of filamentous and amorphous connective tissue that prevents 
strength and flexibility to the skin (21). Furthermore, the dermis accommodates cellular 
residents such as fibroblasts, endothelial cells, mast cells and, under conditions of 
inflammation, macrophages, lymphocytes and leucocytes. The tissue of the dermis has an 
extensive vascular network that is involved in nutrition, thermal regulation and immune 
responses. A variety of appendages, such as hair follicles or sweat and sebaceous glands are 
also derived from this tissue. Underneath the dermis is the hypodermis situated that contains, 
in contrast to the dermis, loose connective tissue and adipocytes as the main cellular exponent 
which represent an energy source for the body. 
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C.2 Dermatological Vehicles 
In clinical situations, a drug is rarely applied to the skin in form of a pure chemical but, instead, 
is normally incorporated in a carrier system, the vehicle (1). Such preparations vary in their 
physicochemical nature from powders through semisolids to liquids. However, a uniform and 
comprehensive classification for dermatological vehicles is currently not yet available. A 
formulation may be classified by its pharmaceutical nomenclature used in pharmacopoeias 
(e.g. cream, ointment, gel), by the principle of the structural matrix (e.g. emulsion, liopsomal 
dispersion) or by macroscopic appearance (e.g. milk, foam, shake). Table 1 gives a simplified 
possible classification of dermatological vehicles. 
 
Table 1 Simple classification of dermatological vehicles 
System Monophasic Diphasic Tri-(multi-)phasic 
Liquid nonpolar solution, 
often designated as oil 
polar solution 
often designated as paint, 
lotion, ect. 
emulsion (o/w, w/o)  
often designated as 
milk, lotion, shake, ect. 
suspension 
often designated as 
paint, shake, ect. 
emulsion (o/w/o) 
often designated as milk, 
lotion, shake, ect. 
suspension 
often designated as paint, 
shake, ect. 
Semisolid water-free polar or nonpolar 
ointment 
water containing polar or 
nonpolar gel 
emulsion (o/w, w/o)  
often designated as 
washable (o/w), 
nonwashable (w/o)or 
amphiphilic (o/w, w/o) 
cream 
suspension 
often designated as 
paste 
emulsion with powder (o/w, 
w/o) 
often designated as cream 
pastes 
Solid powder transdermal patch transdermal patch 
It is obvious that this classification system is a raw simplification of the diversity of external 
formulations. It does not account for many of the newer external formulations (e.g. liposomes, 
microcapsules, microemulsions, ect.) 
Adapted from Surber and Smith, 2005 (1) 
 
C.2.1 Emulsions 
Essentially, an emulsion is a heterogeneous system containing two immiscible phases; a 
hydrophilic liquid phase and a lipophilic or oil phase. If the mixture consists of hydrophilic 
droplets dispersed in oil, we refer to it as water in oil (w/o) emulsion, even when the hydrophilic 
liquid is not water. An oil in water (o/w) emulsion has nonpolar liquid droplets dispersed in the 
aqueous phase; the term oil denotes all lipophilic materials even when they are not true oils in 
the chemical sense, e.g., hydrocarbons (19). Commonly encountered emulsions will have 
average droplet sizes of at least several microns, with a rather broad distribution. The volume 
fraction of dispersed material in emulsions is seldom less than 10 % and sometimes as high as 
90% (28). Beside o/w and w/o emulsions, more complicated systems may arise, generally 
referred to as multiple emulsions. Multiple emulsions are composed of droplets of one liquid 
dispersed in larger droplets of a second liquid, which is then dispersed in a final continuous 
phase. Such systems may be w/o/w emulsions where the internal and external phases are 
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hydrophilic; or o/w/o, which have the reverse composition. Fig.3 gives an overview about these 
emulsion types. 
 
 
Figure 3 Overview about different emulsion types 
 
C.2.1.1 Physicochemical Properties and Preparation of Emulsions 
The preparation of an emulsion requires the formation of a very large amount of interfacial 
area between two immiscible liquids. The work W required to generate a specific area of new 
interface is given by 
 
AiW ∆•= σ     (1) 
 
where σi is the interfacial tension between the two liquid phases and ∆A is the change in 
interfacial area. Since the amount of work that is required to increase the interfacial area 
remains in the system as potential energy, the system is thermodynamically unstable and 
rapidly undergoes any kind of transformations possible to reduce that energy, in this case, by 
reducing the interfacial area. To prevent coalescence or at least to reduce its rate to negligible 
proportions, in almost all practical emulsions, some additive (an emulsifier) is required. The 
additive, an emulsifier and/or stabilizer, may perform two primary functions: (I) lower the 
energy requirements of drop formation (i.e., lower the interfacial tension) and (II) retard the 
process of drop reversion to separate bulk phases. Emulsifying agents may be divided into 
four groups as follows: Adsorbed nonsurfactant ionic materials, colloidal solids, polymers and 
surfactants, which represent the most common stabilisation mechanism (28). Furthermore, the 
type of emulsion that is produced with given hydrophilic and lipophilic compounds, o/w or w/o, 
depends primarily on the property of the surfactant. This characteristic is referred to as 
hydrophilic-lipophilic balance (HLB), that is, the polar-nonpolar nature of the emulsifier. Hence, 
it appears that the type of emulsion is a function of the relative solubility of the surfactant, the 
  
    
  
  
  
w/o 
o/w o/w/o 
w/o/w 
Oil 
Water 
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phase in which it is more soluble being the continuous phase. This is sometimes referred to as 
rule of Bancroft, who observed this phenomenon in 1913 (29). 
In principal, two common methods are used to prepare o/w emulsions. The Continental 
method includes that the emulsifier, the lipophilc phase and parts of the hydrophilic phase form 
a primary w/o emulsion. The final o/w emulsion is obtained due to phase inversion following 
addition of more hydrophilic solution. The second method includes dissolving the emulsifier in 
the hydrophilic phase and the preparation step involves slowly titration with the oil. This 
method is referred to as English method. Each method, however, requires that energy be put 
into the system in some form. The energy may be supplied in a variety of ways, such as 
trituration, heat, agitation or homogenization.  
The rotor stator technology, for example, is a well-established method for time-saving and 
easy emulsion preparation. A typical dispersing aggregate consists of two teeth rings, one of 
them is fixed and does not move - the stator; the other is driven by a motor through the shaft 
and turns around inside the stator - the rotor (Fig.4). The shear forces and bounce effects 
which are created between the running rotor and the stator treat the product mechanically, so 
for example 2 phases can be homogenized in short time. 
 
 
 
Figure 4 Cross-section of a rotor-stator aggregate  
 
C.2.2 Liposomes 
Liposomes were first describes by Bangham in the early 1960s and shortly thereafter were put 
to use as models for biological membranes (30). Liposomes are simply vesicles in which an 
aqueous volume is entirely enclosed by a membrane composed of lipid molecules, usually 
phospholipids. Liposomal vesicles can be large or small and may be composed from one to 
several hundred concentric bilayers. Their size ranges from at least 20 nm to several µm, while 
the thickness of one single bilayer is around 4 nm. With respect to the size and number of 
bilayers, one may distinguish large multilamellar vesicles (MLV`s), and large and small 
unilamellar vesicles (LUV`s and SUV`s, respectively). (31). 
C.2.2.1 Physicochemical Properties and Preparation of Liposomes 
Phospholipids are diesters of glycerol, the sn-1 and sn-2 positions of the glycerol residue being 
esterified with fatty acids of varying length and degree of saturation, while the sn-3 position is 
esterified with phosphoric acid. Normally, a second short chain alcohol is esterified to the 
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second acidic group of the phosphoric acid. This chemical constitution determines the 
amphiphilic nature of the phospholipids that, in turn, enables the association in bilayer shields 
in aqueous media in order to minimize the unfavourable interactions between the aqueous 
phase and the long hydrocarbon fatty acid chains. Such interactions are completely eliminated 
when the sheets fold themselves to form closed sealed vesicles (32).  
 
 
 
Figure 5 A model of geometrical packaging of various amphiphiles into colloidal aggregates. P denotes 
a packing parameter that allows predicting the aggregate shape. From Lasic, 1993 (33) 
 
Fig.5 illustrates how the molecular shape of phospholipids allows the formation of bilayer 
aggregates in a hydrophilic environment, while the molecular geometry of other amphipilic 
molecules leads to formation of micelles or reverse micells.  
In order to produce liposomes, phospholipid molecules must be introduced into an aqueous 
environment. Different methods are reported to obtain liposomes, each of which produces 
vesicles with specific characteristics. Solvent injection methods comprise a simple and 
valuable method. This class of methods consists of several different variations including a 
variety of hydrophilic and hydrophobic organic solvents or their mixtures, being injected into 
different aqueous phases at different experimental conditions (34). The ethanol injection 
method, for example, enables the preparation of unilamellar liposomes when the 
phospholipids, dissolved in ethanol, are injected rapidly into an excess of aqueous medium 
(35). 
 
C.2.3 Microemulsions 
A microemulsion is defined as a system of water, oil and amphiphile, typically a mixture of 
conventional surfactant and alcohol, which is a transparent, optically isotropic liquid system 
that is thermodynamically stable (5). Schulman et. al were the first who introduced the concept 
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of such systems (36,37). Till nowadays, however, there is still uncertainty about the exact 
microstructure of microemulsions.  
 
 
 
Figure 6 Basic dynamic microemulsion structures formed by oil phase (grey), aqueous phase (white) 
and surfactant/cosurfactant film (interfacial). From Kreilgaard, 2002 (5) 
 
Fig.6 gives an overview about assumed arrangements of microemulsion systems. While 
emulsions consist of roughly spherical droplets of one phase dispersed in another (see C.2.1), 
microemulsions may constantly evolve between various structures ranging from droplet like 
micelles to bicontinuous structures. Furthermore, microemulsions may be differentiated from 
emulsions on the basis of the particle size of the dispersed structures that are typically smaller 
than 150 nm, also generating the optically isotropy, even if we consider systems of particular 
microstructure (3). 
The majority of examined microemulsion systems, however, contain irritant ionic surfactans or 
oils such as benzene or hexane, all of which are unacceptable from a pharmaceutical point of 
view. Hence, several authors have focused on formulation of microemulsions with non-irritant 
surfactants, such as phospholipids (11,38). 
C.2.3.1 Physicochemical Properties and Preparation of Microemulsions 
In contrast to conventional emulsions, microemulsions are formed spontaneously when 
admixing the appropriate quantities of the components, without requiring additional mechanical 
energy, and they are physically stable due to their thermodynamic nature (5). As mentioned 
above, the structure can be discontinuous or bicontinuous, depending on the phase ratio from 
hydrophilic to lipophilic phases and surfactant concentrations, respectively. To obtain such 
  
Theoretical Section 
   
 
13 
microstructures, however, a few essential conditions are required: (I) Lowering the interfacial 
tension at the water-oil interface, (II) the formation of a highly fluid interfacial surfactant film 
and (III) penetration and association of the molecules of the oil phase with the interfacial 
surfactant film (37). Lowering the interfacial tension and fluidisation is usually done by 
incorporation of a co-surfactant to the surfactant film, typically a short-chain alcohol. To enable 
further integration of the oil within the interfacial film, the size of the oil molecules should not be 
too large (5).  
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C.3 Characterisation of Dermatological Vehicles 
A number of analytical methods are used for structural elucidation of dermatological 
formulations, such as optical methods (2), rheological inspections (3) ultracentrifugation (4) or 
NMR self-diffusion experiments of formulation compounds (5). However, the use of a single 
method gives usually unsatisfactory results, especially for multi-component systems due to 
their complexity. Beside the droplet size, the interparticulate interactions induced by the 
number of ingredients determine the microstructure of such systems. Thus, in the majority of 
cases a combination of different physicochemical methods for structural investigations of 
dermatological formulations is required. 
 
C.3.1 Optical Methods  
As mentioned in the above chapters, the structures within dispersed systems may range in 
their size from about 10 nm (microemulsions) over several hundred nm (liposomes) up to more 
than several microns (emulsions). Thus, the overall appearance of such systems inherently 
involves some obvious information about comprising structures by simple visual inspection. 
Table 2 shows the optical characteristics for the range of particle sizes typically encountered in 
dispersed systems.  
 
Table 2 Estimation of particle sizes of dispersed structures by visual inspection 
Appearance Tyndall scattering Diameter (µm) 
Two phases None Macro globules 
Pure white None Exceeds 0.5 
White to gray Weak blue 0.3-0.1 
White to translucent Intense blue 0.14-0.01 
Transparent None Less than 0.01 
Modified from Farianto and Rowell, 1983 (2) 
 
However, highly turbid or highly polydisperse samples can wash out a distinguishing 
appearance, owing to multiple scattering, what requires further methods to characterise the 
structure of dispersed systems. Structures in the size range larger than 200 nm can be directly 
visualized with a transmission light microscope (2). Polarized light microscopy provides a tool 
to identify anisotropic materials within dispersed formulations such as solid drug particles or 
liquid crystals formed by encountered surfactants (17,39). Briefly, there are two polarizing 
filters in a polarizing microscope referred to as polarizer and analyzer, situated below and 
above the specimen stage, respectively. A polarising filter permits only one vibration direction 
of the light, while the wave model of common light describes light waves vibrating at right 
angles to the direction of travel of light with all directions being equally probable. When the 
permitted vibration directions of the polarizer and analyzer are positioned at right angles to 
each other, no light can pass through the system, except for a specimen of anisotropic material 
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that will move the vibration direction of the light through the analyzer and finally gives a texture 
of the anisotropic structures of the specimen in the eyepiece of the microscope. 
In order to visualize dispersed structures that are smaller in size than several hundred 
nanometers and that are optically isotropic, transmission electron microscopy (TEM) 
(15,39,40) or scanning electron microscopy (SEM) (41,42) is commonly applied to such 
systems. Most studies described in the literature were performed by TEM using the freeze 
fracture replica technique. In contrast to conventional thin section methods, the replica 
technique theoretically avoids artefacts caused by chemical treatment and dehydration. In 
practice, however, it appeared to be very difficult to clean the replicas and separate them from 
the original matrix (11). However, in case of freeze fracture scanning electron microscopy, no 
replica separation and cleaning is necessary, and the fractured original formulation can be 
observed in the frozen-hydrated state. Specimen preparation for this method involves the 
following steps: First, a small droplet of the formulation is placed on a specimen table and 
rapidly frozen in liquid propane (-196°C). Then the  samples must be rapidly cryo-transferred 
into a freeze-fracturing device, where the fracture is performed at low temperature under high 
vacuum. Due to this treatment, the sample will cleave along a fracture plain with the least 
cohesion. In case of an emulsion, for example, these are the hydrophobic areas of lipids 
stabilized by van-der-Waals forces, which are much weaker than the hydrogen bonds of the 
water domains. By further sublimation of ice to a depth of several nanometers, referred to as 
etching, structural details otherwise hidden in deeper ice layer can be additional exposed. This 
fracture plane is finally coated with a metal-carbon film before scanning electron microscopic 
inspection. 
In principle, a scanning electron microscope detects electrons, emitted from an electron 
source, that are back-scattered from the specimen surface. To achieve this, the specimen 
surface must be coated with a layer of metal, for example platinum with a thickness of a few 
nm, to render the surface conductive. If the metal is evaporated unidirectional at a fixed angle, 
usually 45°, onto the specimen, a shadow effect is generated that gives the image a three 
dimensional appearance. A carbon film finally reinforces this metal layer. Fig.7 shows the 
SEM-micrograph of a representative o/w emulsion. 
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Figure 7 SEM-image of a conventional oil in water emulsion 
 
C.3.2 Determination of the Formulation Type  
There are several physical methods for distinguishing between the types o/w and w/o of 
dermatological vehicles, such as optical observation after blending the sample with a 
hydrophilic/lipohilic dye or simple dilution experiments with the oil or water bulk phase (2,29). 
The practical application of these methods, however, is commonly restricted to simple 
emulsions, since other dispersed systems are more complex in their composition and may 
contain coloured components, which may further complicate an explicit interpretation. A more 
precise method to test the type of a more phasic system is based upon electric conductivity 
measurements (9,29). Electric conductivity is a measure for movable particles with electric 
charge that can carry electricity when a difference of electric potential is placed across a 
conductor. The conductance C in Siemens (S) is the reciprocal of the resistance R in ohms (Ω) 
of the conductor 
 
R
C 1=     (2) 
 
The resistance R is given by 
 
A
lR ⋅= ρ     (3) 
 
with ρ as the specific resistance of the conductor, l denotes its length and A its cross-section 
area in cm2. The specific conductance or electric conductivity κ in S/cm is the reciprocal of the 
specific resistance and described by the term: 
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A
lC ⋅=κ     (4) 
 
To measure the electric conductivity of a dermatological formulation, a pair of electrodes, 
connected to an external electric source, with the distance l and a specific area A each, is 
immersed in the formulation. The ratio l/A is referred to as cell-constant of a specific measuring 
cell. If the water phase is continuous, a current will pass through the emulsion, while a 
continuous oil phase will fail the emulsion to carry the current. The electric conductivity of o/w 
formulations was found to be in the same order of magnitude to the bulk continuous phase 
(43). 
 
C.3.3 Particle Size Measurements 
C.3.3.1 Photon Correlation Spectroscopy  
Photon correlation spectroscopy (PCS) is a method that correlates time depended fluctuations 
of scattered laser light of particles in solution due to Brownian motion with their size. According 
to the Stokes-Einstein equation (Eq.5), the diffusion coefficient D (m2/s) is inversely 
proportional to the mean hydrodynamic radius r of a particle in solution. 
 
ηpi ⋅⋅⋅
⋅
=
r
TkD
6
   (5) 
 
T denotes the absolute temperature, k is Boltzmann`s constant and η is solvent viscosity. In 
principle, the sample (dispersion) is irradiated by a laser beam and a photomultiplier assembly, 
commonly situated at an angle of 90° to the laser b eam, detects the scattered light. For small 
particles, the fluctuation of the scattered light will be faster due to their more rapid diffusional 
motion, compared to larger particles. In practice, a mathematical process is carried out in 
which the intensity of scattered light of an original signal is compared to subsequent time 
delayed signals, referred to as correlation. This process is described by a correlation function 
(Eq.5) that is computed during a PCS measurement: 
 
Γ−
=Γ
22)( DKeg    (6) 
 
with 
 






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2
sin4 θλ
pi nK    (7) 
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where, Γ denotes the delay time and K is the scattering vector that depends on refractive index 
of solvent n, wavelength of the laser beam λ and the detection angle θ. Finally, the 
hydrodynamic radius of the particles can be determined by inserting D (derived from Eq. 6) in 
the Stokes-Einstein equation (Eq.5). The dependence of the method on D, however, 
implements the upper limit of detectable particle sizes: fluctuation and sedimentation of the 
particles might not take place in the sample.  
Another quality criterion that is obtained from PCS measurements is the polydispersity index 
(PI). This index describes the deviation between the theorectical auto correlation function of 
the calculated mean particle size and the correlation fuction adapted from the light scattering 
measurements. Hence, the PI is a measure for the size distribution of the sample. For a truly 
monodisperse particle suspension, the PI is 0. In practice, values between 0.03 and 0.06 are 
supposed to be monodisperse, while PCS measurements that give values above 0.5 are not 
analyzable (44). 
C.3.3.2 Laser Diffraction Measurements 
PCS measurements give unsatisfactory results for larger particles because of the above 
mentioned limitation (see C.3.3.1). In such cases, laser diffraction (LD) measurements may be 
applied. Fig.8 shows a typical LD instrumentation that is commonly used for particle size 
measurements.  
 
 
Figure 8 Optical schematic of LD diffraction instrument. From Barth, 1984 (45) 
 
An unpolarized laser beam is spatially filtered, expanded and collimated. Particles are allowed 
to move across this beam. Diffracted and transmitted light are focused by a lense onto a 
detector that is in the focal plane of the lense. That detector consists of concentric light 
sensitive rings separated by equal thickness insulated gaps. In the middle of the detector plane 
– the optical axis of the laser beam - is a hole located in front of a photodiode. Smaller 
particles scatter a small, definite amount of light through a fixed, but larger, angle, while larger 
particles will scatter a greater amount of light through a smaller angle. This imposes typical 
spherical diffraction patterns that depend on the particle size which is calculated considering 
the distances of the diffracted light circles from the optical axis. According to a theory referred 
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to as Frauenhofer diffraction, the result for the intensity I of the diffraction pattern for a sphere 
of radius r is  
 
( ) 21
0
2





 ⋅⋅
⋅=
x
xJ
II    (8) 
 
where I0 is the intensity at the center of the pattern, J1 is the first-order spherical bessel 
function, and x is given by 
 
F
sr
x
⋅
⋅⋅⋅
= λ
pi2
    (9) 
 
where s is the radial distance in the detection plane as measured from the optical axis and F is 
the focal distance of the lense (45). In praxis, one should consider some fundamental facts 
understanding the meaning of the results of LD particle size measurements: (I) The result is 
volume based, (II) the result is expressed in terms of equivalent spheres and (III) the analyzed 
distribution is expressed in a set of size classes. 
 
C.3.4 NMR Diffusion Experiments 
Pulsed field gradient spin echo NMR (PFGSE-NMR) is an attractive technique to determine 
self-diffusion coefficients of formulation compounds that yields a vast amount of structural 
information without destroying the sample (5,46). Good correlation has also been 
demonstrated between transdermal drug delivery from various vehicles and the molecular 
mobility of the active ingredients in them (5). In principle, PFGSE-NMR uses pulse sequences 
that incorporate pulsed-field magnetic gradients. A gradient is generated that its strength 
varies linearly along the z-axis that is defined by the required constant magnetic field B0 to 
align the nuclei-spins for a NMR experiment. For basic theory of NMR-spectroscopy it is 
referred to the literature (47). The strength of a gradient is experimentally defined in terms of 
its duration δ, its amplitude G and the gyromagnetic constant of the nucleus γ. In principle, the 
application of short gradient pulses (about 3ms) allows tracking the positions of the nuclei 
before (gradient encoding period) and after (gradient decoding period) a specific experimental 
diffusion time (about 100 ms to up to one second). In order to determine diffusion coefficients, 
different gradients are used to impose spatial dependent local (i.e. in the xyz coordinate) 
magnetic fields in the sample so that the signal intensity found after an encoding-decoding 
period depends on the strength of the gradient. The efficiency of decoding depends on how far 
the molecules diffuse in average through the sample; the greater the positional change due to 
diffusion, the poorer the decoding. Hence, self-diffusion of a molecule is directly related to the 
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decay of the signal intensities or peak areas in the recorded NMR spectra when the amplitude 
of the gradient pulses G is modulated according to  
 
DG
I
I g
⋅−∆⋅⋅⋅−= )
3
(ln 222
0
δδγ  (10) 
 
where, Ig and I0 are the intensities in the presence and absence of magnetic field gradient 
pulses, ∆ the experimental diffusion time and D the diffusion coefficient. In order to receive 
undistorted high-resolution NMR spectra, however, optimized pulse sequences are required 
which may consider the number, direction and duration of the radio frequence (rf) pulse that is 
basis for NMR spectroscopy in general and/or the field gradients described above.  
 
Figure 9 Pulse sequence for NMR diffusion experiments. T denotes the effective diffusion time. 
P1,P2,P3,P4 and P5 are 90°pulses, and P6 and P7 are  180° pulses . 
 
Fig.9 shows the pulse sequence that was applied to measure self-diffusion coefficients of 
sodium nicotinate and benzene in the present work. The rf pulse sandwich P1, P2, P6 is 
referred to as stimulated echo and allows the majority of the diffusion period to occur in the 
longitudinal (z) direction. Te describes an additional delay period after the decoding period of 
the experiment that allows so called eddy currents, induced by the magnetic fields of the field 
gradients, to dissipate before NMR signal detection. The rf pulses in combination with the 
alternating gradients (represented by the grey bars above and below the horizontal line in 
Fig.9) further improve the quality of the spectra. This special pulse sequence is referred to as 
bipolar pulse pair longitudinal eddy current delay (48). 
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C.3.5 Ultracentrifugation 
Ultracentrifugation can yield valuable information about the nature, the composition and, if the 
density is known, about the size of dispersed structures. This method is commonly applied for 
stability testing of emulsions (49,50) or for concentration and purification of liposomal 
formulations (51). Furthermore, ultracentrifugation was also used for structural characterisation 
of semisolid multi-phase formulations, typically in combination with further physicochemical 
methods (4,52).  
An (ultra)centrifuge is an instrument designed to apply a rotational force to a mass (particle) 
and if the mass is unrestricted it will move away from the center of rotation. Hence, the 
acceleration of gravity g is replaced by ω2x, where ω is the angular velocity and x is the 
distance of the particle from the center of rotation. Stoke`s law is accordingly modified to  
 
0
2
0
2
9
)(2
η
ωρρ
⋅
⋅⋅−⋅⋅
==
xr
dt
dx
v  (11) 
 
where, v is the velocity of sedimentation, ρ and ρ0 the density of the sedimenting spherical 
particle and the medium, respectively and η0 the viscosity of the medium. The instantaneous 
velocity v=dx/dt of a particle in a unit centrifugal field is expressed in terms of the Svedberg 
sedimantation coefficient s 
 
r
dtdx
s
⋅
= 2
/
ω
    (12) 
 
The force at which a centrifuge is operated is often expressed in terms of the number of times 
that the force of gravity is exceeded. For example, the ultracentrifuge Centricon T-1075 with 
the rotor TFT 7013 (Kontron Instruments, Mailand, Italy) used in the present work to fractionate 
the formulations produces a force in between 221290 and 448610 g, depending on the 
distance from the centre of rotation. 
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C.4 Drug Delivery Across the Skin 
The aim of drug application on the skin may be targeting the drug to three anatomical 
locations, namely the skin itself (topical delivery), deeper tissue layers (regional delivery) and 
the systemic circulation (transdermal delivery)(1). The advantage of topical or regional drug 
delivery is clear, because the treatment of the skin with a systemically applied drug may lead 
to adverse effects, and only a small fraction of the applied drug will reach the target site. But 
there are also reasons to favor the transdermal route in systemic drug delivery. Transdermal 
drug delivery circumvents variables that rest on the anatomical and physiological properties 
along the gastrointestinal tract, for example pH gradient and nutrition, and the first pass 
metabolism is bypassed. Furthermore, the use of special drug delivery systems (for example 
Transdermal Therapeutic Systems, TTS) provides controlled administration and duration of 
drug action. The quantity of available drugs that may be candidates for the transdermal 
delivery route, however, is limited by several factors. The amount of permeable drug is limited 
by the skin barrier properties and the physicochemical properties of the penetrant, which allow 
only very potent drugs as possible candidates for transdermal administration. Furthermore, the 
drug of choice must be compatible with the matrix of the delivery system that should not irritate 
or sensitize the skin itself (53). 
Three drug related processes must be taken into consideration when a drug preparation is 
applied on the skin: (I) The release of the penetrant from the vehicle, followed by (II) its 
penetration through the different skin barriers and (III) its activation of the desired 
pharmacological reaction. Fig.10 gives an overview about the drug flux that may arise following 
application of a suspension vehicle. The drug may undergo any or all of the following events. 
First, the drug molecules must dissolve to enable its diffusion through the vehicle to the 
vehicle-stratum corneum interface. For the drug to move trough the skin it must partition into 
the stratum corneum and diffuse within this almost impermeable layer. Some drug may bind at 
so-called depot-site; the remainder diffuses to deeper tissues of the epidermis, meets a 
second interfacial layer and partitions in the viable epidermis (54). 
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Figure 10 Some stages in percutaneous absorption from a vehicle with suspended drug. From Barry, 
1983 (54) 
 
For most hydrophilic and amphiphilic penetrants, diffusion through the stratum corneum will be 
the rate-limiting step in percutaneous absorption, whereas lipophilic substances are favored to 
penetrate this layer. If very lipophilic drugs are used, however, the viable epidermis can act as 
a rate-limiting factor in permeation across the skin (53). In this case, clearance rate from the 
barrier will govern percutaneous absorption, while the thermodynamic activity in the vehicle 
may approach that in the viable epidermis directly below the barrier (55). 
The amount of drug permeated through the skin per unit time and unit area is defined as the 
drug flux J, that is described by Fick`s first diffusion law:  
 
dx
dcD
Adt
dmJ ⋅−=
⋅
=    (13) 
 
where m denotes the drug amount, t the time, A the effective diffusion area and D the diffusion 
coefficient (cm2/s). dc/dx is the concentration gradient over a distance. Assuming the 
conditions of a perfect sink (receiver concentration negligible, therefore zero) an infinite donor 
concentration CD, rate limiting membrane (skin) diffusion and partition between donor vehicle 
and rate limiting membrane, Eq.13 can be expressed as: 
 
h
CKD
Adt
dmJ D⋅⋅−=
⋅
=  (14) 
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K represents the distribution coefficient of the diffusant between the vehicle and the membrane 
(skin) and h is the thickness of this membrane. Because an exact determination of h and D is 
difficult, these parameters may be summarized in term of the permeability coefficient P (cm/s): 
 
h
KDP ⋅=    (15) 
 
The permeability coefficient can be regarded as a characteristic for a specific substance-
membrane system and is, beside the drug flux and the totally permeated drug amount after a 
specific time, a common measure for steady state drug permeation. 
 
C.4.1 Permeation Routes  
The permeation of drugs through the skin includes the diffusion through the intact epidermis 
and trough skin appendages, for example sweat glands and hair follicles. However, the 
appendages occupy only 0.1% of the human skin surface so that the contribution of these 
shunt pathways to transdermal permeation is usually considered to be small (56). Only an 
increasing molecular weight of the penetrant may lead to a significant role of the appendageal 
route (57).  
As mentioned in chapter C.1.2, the stratum corneum represents the main barrier of the skin. 
Theoretically, there are two pathways through this layer (Fig.11): A transcellular (across the 
corneocytes and the lipid matrix) and an intercellular way (via the intercellular lipid domains 
between the corneocytes). In both cases, however, the permeant has to pass the intercellular 
lipid matrix.  
 
 
 
Figure 11 Permeation routes through the stratum corneum. From Moghimi, 1999 (58) 
 
Intercellular lipids are arranged in multiple layers, containing both, polar and nonpolar 
components. This suggests that hydrophilic and lipophilic penetrants diffuse through different 
domains in the lipid matrix. The transcellular pathway is generally the unfavoured route for a 
drug to permeate through the stratum corneum because of the high diffusional resistance of 
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the cornified cells (59). Only hydrophilic molecules such as water or short-chain alcohols seem 
to prefer the transcellular pathway (55). 
 
C.4.2 Factors Affecting Drug Permeation Through the Skin 
Several biological and physicochemical parameters may influence drug permeation across the 
skin (54). The physicochemical factors that control the passive diffusion of a substance from a 
vehicle into and across the skin are determined by the molecular properties of the substance, 
the vehicle and the skin. Hence, the following interactions may have impact on drug delivery: 
drug-skin, vehicle-skin, drug-vehicle and drug-vehicle-skin. Alterations the vehicle may 
undergo after application, commonly due to evaporation of volatile components, represent a 
further crucial parameter that may affect drug permeation. 
The biological factors include skin age, body region, metabolism and hydration. At different 
body sites, the composition and finally barrier properties of the stratum corneum may vary, 
what includes differences in its thickness, number of cells or, sometimes overemphasized- the 
density of skin appendages (60). Especially the viable epidermis contains several enzyme 
systems that may catalyze processes such as oxidation, reduction, hydrolysis or conjugation. 
Therefore skin metabolism may have additional impact on transdermal delivery of drugs. The 
effect of age is rather due to the smaller surface-to-volume ratio in case of newborn infants 
compared with adults than an effect of lower barrier function of younger skin (53). Skin 
hydration is a crucial and possibly the most frequently investigated factor affecting drug 
permeation. In practice, there is often a combination of these factors that contribute to (trans-) 
dermal drug permeation. 
C.4.2.1 Skin Hydration and Occlusion 
The normal degree of hydration of the stratum corneum is between 10 to 30% of its own 
weight (see also C.1.2). Occlusion hydrates the keratin in corneocytes and increases the water 
content between adjacent intercellular lipid lamellae. For hydrophilic substances, released from 
an aqueous delivery device, the partition coefficient between stratum corneum and the vehicle 
increases up to unity (54). Furthermore, skin temperature generally increases form 32°C to as 
much as 37°C under occlusive conditions. Of various  approaches employed to enhance the 
percutaneous absorption of drugs, occlusion is the simplest and perhaps one of the most 
common methods in use. Beside obvious improved penetration of hydrophilic drugs, however, 
a trend of occlusion-induced penetration enhancement with increasing penetrant lipophilicity is 
also apparent. A possible explanation is that hydration magnifies the aqueous regions of the 
intercellular lipid domains, increasing the hydrophilic character of the stratum corneum. It 
follows that this, in turn, leads, to a reduction in the stratum corneum- viable epidermis 
distribution coefficient. This finally favors the kinetics of transfer of penetrants from the stratum 
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corneum to the viable epidermis. The limit of this mechanism of enhancement would be a 
complete insolubility of the penetrant in the aqueous phase of the stratum corneum or sterically 
hindered penetration of the substance, for example due to large molecular size (61). However, 
a number of studies have shown that hydration-induced skin permeation enhancement 
appears to be not only a function of lipophilicty and hydrophilicity but also seems to be 
chemical class dependent (62,63).  
C.4.2.2 Evaporation of Volatile Vehicle Compounds Following Application 
In clinical and experimental situations, most dermatological vehicles undergo considerable 
changes following application to the skin, most likely due to evaporation of volatile 
components, supported by mechanical agitation associated with application of the product (1). 
It is obvious that such an alteration in vehicle composition, which may increase the activity of a 
drug in the residual vehicle phase, is possibly necessary for adequate, although generally low, 
percutaneous absorption and efficiency. Most studies on this aspect report on the changes in 
solvent concentration after application, often investigated with volatile solvent mixtures. An 
early work of Coldman et al. showed that volatile solvent systems could be used to generate 
states with increased thermodynamic activity (supersaturation) that lead to an increased 
percutaneous absorption when compared to saturated solutions (7). Chiang et al. investigated 
the permeation of minoxidil form water/ethanol/propylene glycol mixtures as volatile vehicles 
what confirmed the work of Coldman (16). They further report on drug precipitation that leads 
to a markedly depression of drug delivery relative to the supersaturated state. An interesting 
publication reports on a drug delivery device where the evaporation of ethanol from an ethanol-
water mixture increased the vehicle-skin partition coefficient of the active substance, 
compensating for the loss of drug due to skin permeation (64). The consequence is a near 
zero order flux over the entire application time and an absence of a large excess of drug in the 
donor reservoir. To summarize, the evaporative concentration effect may even force the drug 
out of the solution and superimpose a dissolution dependency in the delivery rate.  
Other investigations focus more detailed possible changes dermatological formulations may 
undergo following application, but without correlating the observations with drug delivery 
(17,18,65). The general, but valuable conclusion of these studies is that respective phase 
diagrams may reflect the arising structures during evaporation.  
The dependence of drug delivery on alterations dermatological formulations comprising coarse 
and colloidal structures undergo due to evaporation of volatile components, however, does not 
appear to have been considered to any great extent in the literature. Mueller-Goymann and 
Alberg related evaporative changes of water containing hydrophilic ointment that was modified 
by incorporation of ethanol with permeation of hydrocortisone-21-acetate in vitro (66). They 
reported on a reduced loss of volatile components after the incorporation of ethanol, likely due 
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to fixation of the alcohol in the microstructure of the ointment. The liberation kinetics across an 
artificial membrane could be related to the arising drug concentration, but permeation kinetics, 
however, was equal from both formulations. This was accredited to penetration enhancing 
effects of the ethanol. The effect of percutaneous absorption of hydrophilic model drugs on the 
emulsion type after non-occlusive finite dose application is presented by Ferreira et. al (67). 
Hummel and Imanidis demonstrated that obviously varying in-vitro skin permeation of 
ibuprofen from several non-occlusively applied multi-phasic dermatological formulations was 
only governed by the continuous phase drug concentration of the vehicles, independently of 
existing dispersed structures. The back diffusion of the lipophilic model drug into the dispersed 
phases compensated for the influence of the rising overall drug concentration due to 
evaporation of volatile components, so that linear drug flux with time was observed (4). 
C.4.2.3 Drug-Skin Interactions 
Potential interactions of the active ingredient with the skin include hydration effects and binding 
of the drug to tissue components. It is possible that some drugs, which can rapidly penetrate 
the skin to yield tissue concentrations that are high enough exert an osmotic effect, may 
increase skin hydration (54). The so-called reservoir effect of topical steroids represents a 
common example that involves drug-stratum corneum binding. This effect, however, is not 
restricted to this substance class. Nicotine, caffeine or cationic β-blocking agents are also 
reportedly retained in the skin after application, followed by a delayed release (68). Another 
drug-skin interaction is proposed by Al-Saidan, who reports on a self-permeation enhancement 
of ibuprofen, likely due to disruption of stratum corneum barrier (69).  
C.4.2.4 Drug-Vehicle Interactions 
Drug vehicle interactions include the thermodynamic activity of the drug in the vehicle that is 
related to solute drug concentration in the vehicle and the activity of the drug. The maximum 
drug transfer into the skin takes place when the vehicle is saturated with the drug at the 
vehicle-skin interface (1). In this situation, the thermodynamic activity is 1. In some cases, 
however, thermodynamic activity may be > 1, for example in a supersaturated state due to 
vehicle evaporation (see C.4.2.2). Hence, when the system deviates from ideality, the 
concentration must be replaced by activity αD 
 
DDD C⋅= γα   (16) 
 
where, CD denotes the donor concentration and γD is the activity coefficient. Schwarb et al. 
reported on a supra-proportionally increased flux of fluocinonide through a silicon membrane 
with increasing drug concentration, likely due to increasing thermodynamic activity, while in 
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vivo skin penetration of the drug was only increased by the factor of which the magnitude of 
concentration in the respective formulation was increased (6). 
A further drug-vehicle interaction that may affect drug permeation is the formation of ion pairs 
of charged drugs with counter ions present in the vehicle. Valenta et. al. found that fluxes of 
charged lignocaine salts were significantly increased in the presence of organic counter ions, 
while inorganic salts did not influence the permeation kinetic (70). Several publications that 
deal with cationic substances and fatty acids as counter ions support this ion pair approach as 
a possible permeation enhancing effect of the fatty acids (71,72). Furthermore, in some cases 
drug permeation through the skin is not governed by the impermeability of the stratum 
corneum, for example when the horny layer is damaged or drug diffusion within the vehicle is 
exceptionally slow. In such a case, the release rate of the drug from the vehicle provides the 
rate-limiting step in overall diffusion, and the skin functions as a perfect sink (73). 
C.4.2.5 Vehicle-Skin Interactions 
Despite the fact that a drug delivery vehicle should be `inert`, especially vehicles commonly 
used for topical treatment reportedly have additional effects to the requirement that it should 
readily release the active moiety for the therapeutic effect (1). The application of 
pharmaceutical vehicles, such as gels, emulsions, creams or ointments, may superimpose 
further changes of the integument and finally may affect its permeability. This mechanism of 
action will probably be a solvent action on the stratum corneum, a hydration effect or a 
temperature effect (54). The hydration effect is generally due to occlusion effects of the 
vehicle. Thus, it is obvious that oily materials retard more efficient moisture loss from the skin 
than for example hydrogels or oil in water emulsions. A detailed description of hydration effects 
and its influence on skin permeation is given in chapter C.4.2.1. Furthermore, under occlusion 
or under the influence of a cooling vehicle, the skin temperature may increase or decrease a 
few degrees, which may affect the diffusion coefficient of a substance due to its temperature 
dependence. However, any consequent altered permeability is small compared to the more 
dramatic effect which the resultant increased hydration causes (54). An auspicious tool to 
improve cutaneous delivery rate is the application of appropriate vehicles, such as 
microemulsions or liposomes, which may reduce skin barrier function due to direct interaction 
with the stratum corneum, or to include molecules in the delivery device that may reversibly 
reduce the barrier resistance of the skin. Such entities are known as penetration enhancers.  
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C.4.2.6 Mode of Action of Penetration Enhancers 
Three permeation enhancement strategies may be postulated based on Ficks first law (see 
C.4): (i) reducing diffusional resistance, that increases the diffusion coefficient D, (ii) increasing 
the partition coefficient K between the stratum corneum and the vehicle, and (iii), increasing 
the concentration in the vehicle CD. Disordering the extracellular stratum corneum lipid matrix 
can increase the diffusion coefficient. Oleic acid, for example, has been shown to induce 
phase separation in the stratum corneum lipid domains which results in reduced barrier 
function (74). Azone, dimethyl sulfoxide (DMSO) and different terpenes are other agents that 
may provoke lipid disorder in the stratum corneum and hence may increase drug diffusivity 
(56). Another mode of action is to increase drug solubility in the skin and hence increase the 
partition coefficient between the stratum corneum and the vehicle. Enhancers that may act in 
this way are propylene glycol, ethanol, transcutol and N-methyl pyrrolidone (75). Fig.12 
represents postulated sites for penetration enhancers to act in the intercellular domain, which 
is probably their most crucial location of action. An interaction with the polar head groups of the 
lipids, site A in the diagram, will lead to a disturbing of the hydration spheres and alterations in 
the head group interactions should upset the packing plane. 
 
 
Figure 12 Postulated sites for penetration enhancers to act in the intercellular domain, from Barry, 1987 
(76) 
 
This mechanism should promote the diffusion of polar penetrants due to increased fluidity of 
the domain that, in turn, allows more aqueous fluid to enter the tissue, increasing the water 
volume between the lipid bilayers. A second important feature is that a disrupter of the 
interfacial structure will tend to reflect into an alteration of the packaging of the lipid tails. The 
hydrophobic route thus becomes more disordered and more readily to be traversed by a 
lipophilic penetrant (site C in the diagram). Additional effects of an accelerant on the aqueous 
region may change temporarily the bulk constitution of the domain. For example, high enough 
concentrations of ethanol may penetrate into the aqueous region of the tissue to alter the 
solubilizing ability of this site, so that the operational partition coefficient now favors a higher 
drug concentration in the skin. Many penetration enhancers should, because of their structure, 
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insert between the hydrophobic tails of the intercellular lipid bilayers (site C in the diagram), so 
upsetting their packaging, increasing their fluidity and thus permitting easier diffusion of lipid 
penetrants. The changed lipid packaging can reflect back to cause some disorder in the polar 
head group region and so improve polar route penetration. (76). 
C.4.2.7 Mode of Action of Microemulsions 
Even though numerous individual studies of structure, self diffusion coefficients of compounds, 
formation and transdermal delivery performance of various microemulsion systems have been 
published, little is known about the correlation between these parameters (5,8,9,10,11). 
However, two basic trends are observed from the reported studies that may contribute to the 
favorable drug delivery properties of microemulsions: high drug load capacity and penetration 
enhancer effects. High drug load capacity increases drug flux due to a larger concentration 
gradient, which is more drug-vehicle interaction than vehicle-skin interaction. A possible 
explanation for favored penetration enhancer effects of microemulsions, compared to 
conventional vehicles such as emulsions, is that microemulsions include ultra low interfacial 
tension between lipophilic and hydrophilic domains. This ensures an excellent surface contact 
between the skin and the vehicle constituents over the entire application area. As 
consequence, amphiphilic and lipophilic ingredients may reach the stratum corneum more 
easily and, hence, they may interact with stratum corneum lipids as discussed above for 
penetration enhancers (see chapter C.4.2.6). Furthermore, the high content of lipophilic and 
aqueous phase, which are assumed to fluctuate continuously, facilitates transition of both 
lipophilic and hydrophilic drugs from the-typically hydrophilic-vehicle to the lipophilic stratum 
corneum (5). However, the uncertainty about the exact microstructure of microemulsion 
systems makes it difficult to link their structure accurately to their drug delivery abilities, which 
may be further complicated by their possible dynamic, continuously fluctuating nature. 
C.4.2.8 Mode of Action of Liposomal Vesicles 
Even though liposomes have been proposed to penetrate the skin, the use of liposomal 
vesicles is one of the most controversial methods to increase drug transport across the skin 
(22). Mezei and Gulasekharam published the first work on interactions between liposomal 
vesicles and skin (13). They reported that the application of drugs with liposomes favored the 
deposition of the active moiety in the epidermis and dermis. Although they strongly suggested 
that the vesicles penetrated the skin, this implication was received with a lot of skepticism and 
initiated a number of studies. Two publications from 1984 and 1985, however, could not 
confirm intact liposome penetration as suggested by Mezei and Gulasekharam (77,78). Verma 
et al. investigated the penetration of a hydrophilic fluorescence probe, carboxyfluorescein, that 
enabled a confocal laser scanning microscopy study of the skin after treatment with a 
liposomal vehicle (12). The results lead them to assume that the vesicles increase the skin 
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penetration of entrapped and non-entrapped carboxyfluorescein. Other studys showed that 
only vesicles with proper composition may penetrate the skin, as reported by Cevc, 2004, who 
introduced Transfersomes® (15). Transfersomes® are sufficiently deformable vesicles due to 
incorporation of additives in the bilayer. These much more deformable vesicles may squeeze 
themselves into the smallest pores. Touitou et al., 2000, developed a new system in which 
liposomes are combined with ethanol, referred to as ethosomes (14). Most probably the 
ethanol decreases the interfacial tension of the vesicles and, thus, makes them more 
deformable and elastic, as described for the Transfersomes® above. Additionally, the ethanol 
itself may disturb the stratum corneum lipids, facilitating a synergistic mechanism with the 
ethosomes by virtue of their deformable particulate nature. A former study of the same group 
compared liposomal vesicles with penetration enhancers (79). Interestingly, they observed that 
liposomes could act as an excellent reservoir in the skin, while penetration enhancers 
increased the drug transport across the skin. Other authors claim that skin treated with 
liposomes reveals vesicle fusion. This yields a structural breakdown of the liposomal bilayer. 
Hence, fusion of the phospholipids with the intercellular lipids of the stratum corneum may 
induce ultrastructural changes in this region with the consequence of reduced skin barrier 
function (80). Phospholipids, however, may exist, depending on the temperature and the 
nature of their fatty acid chains, in a highly ordered state, the gel-state, or a state where the 
individual lipid molecules possess greater freedom of motion, the liquid crystalline state. 
Hence, it may also be a crucial factor if gel state or liquid state liposomes are applied on the 
skin. From several studies, a trend can be observed that the more flexible liquid state 
liposomes are favoured to penetrate the skin (81,82). To summarize, in spite of the great 
number of investigations in order to examine the mode of action how liposomes interact with 
the skin, it is still not well understood whether they penetrate as entire liposomes or not.  
 
C.4.3 In-Vitro Permeation Experiments 
Different in-vitro methods to test percutaneous absorption are offered in the literature, for 
example the isolated perfused bovine udder (83) or the perfused pig ear (84). However, 
diffusion experiments across excised human or animal skin are the most common methods in 
use. The advantage of such in-vitro methods is, in addition to the avoidance of animal 
experiments or expensive and time consuming experiments in-vivo in human, that the 
investigator may control the experimental environment and so elucidate individual factors that 
modify drug penetration. The most commonly used diffusion system is the diffusion cell 
described by Franz, where the membrane is mounted horizontally in the diffusion cell (85). The 
chamber beneath the membrane holds the receptor fluid that may be collected frequently 
through a side arm for analysis (Fig.13). Two advantages of this experimental setup over other 
in-vitro testing systems in order to simulate clinical situations are obvious; (I) It allows to apply 
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the delivery vehicle non-occlusively and (II) it allows to apply a small amount of donor vehicle 
(finite dose).  
 
 
Figure 13 Diagrammatic illustration of a Franz diffusion cell, from Chien, 1987 (86) 
C.4.3.1 Membranes for In-Vitro Permeation Experiments 
In-vitro release testing through a membrane with negligible diffusional resistance can, in 
principle, reveal a lot about the physical attributes (solubility, microscopic viscosity, emulsion 
state, ect.) of a semisolid dosage form. Hence, such liberation experiments serve primary as a 
quality control tool to ensure batch to batch reproducibility. The kinetic and thermodynamic 
processes underlying the release of drugs from dermatological formulations, however, usually 
differ in fundamental ways from the processes that determine the partition and uptake of the 
drugs from clinical application of the same dosage form (87). The lipoidal nature of the stratum 
corneum suggests that lipophilic membranes may provide better in-vitro models for permeation 
studies. Silicon membranes are of particular interest in this context (88). Undoubtedly, the best 
membrane for studying transdermal drug diffusion in vitro is excised human or animal skin 
(73). 
C.4.3.2 Pig Ear Skin 
Porcine skin is a well-accepted and readily available model for human skin and is often used to 
assess dermatological formulations in-vitro, for what excised skin from the pig ear has become 
increasingly used for this purpose (89). Lopez et al. investigated the composition and structure 
of pig stratum corneum based on the action of different solubilizing agents (90). They report on 
strongly similar lipid composition and structural organisation of the pig stratum corneum as 
emphasized in chapter C.1.2 for human stratum corneum. Sekkat et al. evaluated stratum 
corneum barrier function of pig skin in-vitro during its progressive removal by adhesive tape 
stripping using the technique of transepidermal water loss and impendance spectroscopy (89). 
Comparing the results with in-vivo data obtained from human strongly supports the validity of 
the porcine membrane as good in-vitro model. Table 3 gives the fluxes of four model 
compounds of widely varying polarity through various skin membranes that are commonly 
used for in vitro investigations. It is obvious that pigskin appears as the most suitable model for 
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human skin. Somewhat unexpected, SkinethicTM HRE, a human reconstructed epidermis 
model that recently has attracted interest as an alternative for excised human epidermis, is 
much more permeable for all investigated compounds.  
 
Table 3 Permeation rate (flux) of different test compounds measured with various skin membranes in 
vitro 
Skin Terbinafinea Clotrimazolea Hydrocortisonea Salicylic acidb 
Human 0.01 0.02 0.023 21.9 
Domestig Pig 0.01 0.02 0.011 12.7 
Rat 0.55 0.055 1.16 24.2 
SkinethicTM HRE 0.37 18.8 5.29 152.8 
Test compounds were applied as a 1% solution in apropylene glycol, bPropylene glycol/water 9/1. Values 
denote µg/cm2/h. Modified from Schmock et al., 2001 (91) 
 
C.4.3.3 Assessment of Skin Barrier Integrity  
There are three commonly used techniques to establish the barrier integrity of skin. (I) 
Measurement of the transepidermal water loss, (II) tritiated water permeability measurements 
and (III) electric resistance measurements (92,93). The application of a Tewameter for the 
determination of the transepidermal water loss provides a noninvasive and rapid alternative to 
tritiated water permeation for assessing skin barrier functions. The principle of the 
measurement is based upon an open chamber system with two humidity and two temperature 
sensors, placed at 2 and 4 mm distance from the skin surface. This measurement setup allows 
to estimate the evaporation gradient on the skin surface, which is described by Fick`s first 
diffusion law:  
 
dl
dsAD
dt
dm
⋅⋅−=    (17) 
 
where dm/dt denotes the diffusion stream across the open chamber, expressed as transported 
mass of water per time. A is the exposed area and ds/dl the change of the density over the 
entire distance. D is the diffusion coefficient of water vapour in the air. Common values for the 
transepidermal water loss vary widely, depending on the body site and environmental 
conditions. Disturbance of the integrity of the skin barrier, however, leads to drastically 
increase in the loss of endogenous water (94). 
C.4.3.4 Skin-Vehicle Distribution Coefficient 
The dominant role, which the distribution coefficient of a penetrant between a specific vehicle 
and the stratum corneum may play in controlling the steady state drug flux across the skin is 
emphasized in chapter C.4.2.6. Common methods to estimate partition coefficients are based 
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upon equilibrium partitioning experiments. Typically, isolated, accurately weighted stratum 
corneum pieces are incubated with the specific substance dissolved in the vehicle. Hence, 
distribution coefficients may be derived from quantification of the remnant in the vehicle or from 
analyzing the drug amount within stratum corneum after extraction with a suitable solvent 
(95,96). According to these authors, a common method to isolate stratum corneum is based 
upon the treatment of excised skin with trypsin solution for several hours. Then, the stratum 
corneum may be carefully peeled off from the underlying epidermal cells and, after treatment 
with trypsin inhibitor solution to prevent further degradation, dried and stored in a desiccator 
over silica gel. 
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D.1 Effect of microstructure and continuous phase drug concentration of multi-
phase dermatological formulations on hydrophilic drug skin permeation and 
stratum corneum distribution 
 
Abstract 
The purpose of this study was to investigate the influence of microstructure of occlusively 
applied multi-phase o/w formulations on transdermal permeation of hydrophilic model drugs 
(sodium nicotinate, caffeine and benzyltrimethylammonium chloride) across pig ear skin in 
vitro. A concept for the interpretation of drug permeation is proposed that considers continuous 
phase drug concentration as the driving force for permeation, drug distribution between 
stratum corneum and formulations and drug diffusion in the stratum corneum. The studied o/w 
formulations consisted of phospholipids, triglycerides, emulsifier, ethanol and water in 
proportions covering a wide range of values and phase ratios of dispersed to continuous 
phase. Depending on the individual composition, coexisting dispersed phase structures, such 
as liposomes, emulsion droplets and microemulsions in a hydrophilic continuous environment 
were formed, as attested by ultracentrifugation experiments. Particle size measurements and 
NMR diffusion experiments revealed a droplet-like structure for the detected microemulsions. 
For all tested drugs, these microemulsion structures had the potential to increase significantly 
the diffusion coefficient of the drug in the stratum corneum, while increasing dispersed phase 
generally decreased drug distribution coefficients between stratum corneum and the 
formulations. Hence, the proposed concept offers a tool to delineate the effect of 
physicochemical formulation parameters and of the interaction of formulation structures with 
the skin on regulation of drug skin permeation. 
 
1 Introduction 
In clinical practice, drugs are incorporated in a vehicle in order to be applied to the skin for 
topical or systemic therapy (1). Vehicles typically consist of several components that are often 
not mutually miscible, thus forming separate phases. The phases of such a formulation are 
intermixed, producing macroscopically homogeneous systems. On the microscopic level, 
however, these phases form different structures which may be identified using a combination 
of methods including microscopy, NMR spectroscopy, and rheology measurements (2,3,4). 
Formulations for cutaneous application are developed and optimized with respect to a host of 
criteria such as applicability, tolerability, stability and foremostly efficacy, which comprises 
duration and strength of pharmacological action. It is meanwhile widely acknowledged that the 
formulation of a drug product, which is conceived as a drug delivery system, regulates 
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transdermal permeation. This regulation may take place not only based on physicochemical 
principles such as diffusion and partitioning of the active ingredient but also by an interaction 
with the absorptive epithelium, i.e., the epidermis, affecting its permeability of the drug. 
Liposomal vesicles (5,6,7,8,9,10) and microemulsions (11,12,13,14), for example, represent 
classes of drug vehicles which may affect skin permeation by reducing the transport barrier 
function of the stratum corneum. However, despite the efforts made to date to elucidate the 
influence of the formulation on skin absorption on a mechanistic basis, there is still no unifying 
theory that allows safe prediction of the process (15). This theory should take into account 
thermodynamic and methodological aspects (16,17). 
In a separate manuscript (18), a concept for the interpretation of transdermal drug permeation 
using multi-phase formulations was proposed by the authors that considers drug distribution 
among the phases of the formulation and postulates that continuous phase drug concentration 
alone governs drug permeation kinetics. With the derived quantitative model it was possible to 
explain in vitro skin permeation of sodium nicotinate, a hydrophilic drug, for representative o/w 
vehicles that were applied under non-occlusive conditions. This model could also accurately 
explain changes of the permeation rate occurring because of the alteration of the inner 
structure of the formulation over time during the application (18). This alteration was because 
of the evaporation of volatile vehicle components. No interaction of the vehicle with the 
epidermis was evident in that study. In a previous work, the proposed concept was further 
shown to be consistent with the permeation behaviour of a lipophilic drug (ibuprofen) through 
the epidermis for o/w vehicles applied non-occlusively (19). 
The goal of the present work was to implement the above concept in the occlusive application 
of vehicles similar to those used before (18) in order to confirm its validity and, importantly, use 
it as a tool to detect possible interactions of the vehicle with the stratum corneum under 
experimental conditions allowing no vehicle alteration. In this context, the developed model is 
employed to delineate the regulation of skin permeation by the formulation as a result of 
controlling continuous phase drug concentration and/or as a result of affecting skin 
permeability of the drug due to a vehicle-stratum corneum interaction. Gaining a deeper 
understanding of the mode of this interaction and its dependence on the physicochemical 
structure of the formulation rounds up the goal of the present work. 
The studied o/w formulations consisted of phospholipids, triglycerides, emulsifier, ethanol and 
water in proportions covering a wide range of values and formed depending on the 
composition coexisting phase structures, i.e., liposomes, macro-emulsion oil droplets and 
microemulsion aggregates in a hydrophilic continuous environment (18). These formulations 
were designed specifically for investigating the effect of structure and mass fraction of the 
formed phases on transdermal delivery. Three hydrophilic model drugs with different structure 
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and charge, sodium nicotine, benzyltrimethylammonium chloride (BTA-Cl) and caffeine were 
investigated. 
The influence of the used drug on phase formation of the formulations was examined. Methods 
were developed and optimized for determining the free drug concentration in the continuous 
phase of the formulations. Permeation experiments were carried out in vitro using pig ear skin 
as a model for human skin (20). A practically infinite amount of formulation was applied in 
order to determine steady state flux values that facilitate the data evaluation. This was deemed 
appropriate for reaching the specific goals of this study. The interaction of the vehicles with the 
stratum corneum was investigated by separately evaluating the diffusion coefficient of the drug 
in the stratum corneum and its distribution coefficient between stratum corneum and the 
continuous phase of the formulation (21,22,23). 
 
2 Materials and methods  
2.1 Materials 
Nicotinic acid was purchased from Sigma (St. Louis, MO, USA). Benzyltrimethylammonium 
chloride (BTA-Cl) was purchased from Fluka Chemie GmbH (Buchs, Switzerland) and caffeine 
was a gift from Sandoz AG (Basel, Switzerland). Mygliol 812N®, medium chain triglycerides, 
was a gift from Hüls AG (Witten, Germany). Phospholipon 80, a soy bean lipid extract with 76 
weight-% phosphatidylcholine, and NAT 8539®, a mixture of 75 weight-% Phospholipon 80 and 
25 weight-% ethanol, were gifts from Phospholipid GmbH (Cologne, Germany). Polysorbate 
20, sodium dihydrogenphosphate dihydrate, sodium azide and 1-octanesulfonic acid sodium 
salt monohydrate, puriss.p.a., were purchased from Fluka Chemie GmbH (Buchs, 
Switzerland). Alcohol dehydrogenase 100mg (3.4ml) suspension, aldehyde dehydrogenase, 
lyophilized powder, 250U and NAD, free acid, grade II, approx.98%, were purchased from 
Roche Diagnostics AG (Rotkreuz, Swizterland). Tetra-n-butylammonium hydrogensulfate 
(LiChropur), CombiTitrant5, a one-component reagent for the volumetric Karl Fischer titration, 
methanol and tetrahydrofurane, (LiChrosolv), were obtained from Merck (Darmstadt, 
Germany). Acetonitril (HPLC, gradient grade) was obtained from Biosolv (Valheesward, 
Netherlands). 0.25% Trypsin, 1mM EDTA solution was purchased from LuBioScience 
(Lucerne, Switzerland). All other chemicals and reagents used in this study were of analytical 
grade. Bidistilled water was used in all cases. 
2.2 Methods 
2.2.1 Manufacturing of the formulations 
The study formulations (for composition see Table 1) were prepared by mixing NAT 8539® and 
tocopherol with the ethanol (mixture1), dissolving the respective model drug (nicotinic acid, 
BTA-Cl or caffeine) in aqueous phosphate buffer (β=0.01) adjusted to pH of 7.4 (mixture 2) 
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and suspending polysorbate 20 in Mygliol 812N® (mixture 3). For manufacturing CF10 and 
CF50, mixture 2 was first added to mixture 3 and homogenized for 5 minutes at 20000 rpm 
using a Polytron Pt 3000 (Kinematica AG Littau, Switzerland). Subsequently, mixture 1 was 
added and the product was homogenized once again for 5 minutes. E was produced by adding 
mixture 2, additionally containing the ethanol, to mixture 3, and LD was obtained by adding 
mixture 1 to mixture 2, followed by homogenization as above. Xanthan gum was added at the 
end to the formulations followed by further homogenization for 30 seconds, except for the 
formulations that were used for ultracentrifugation (see 2.2.2). The gel was produced by 
adding 0.5 weight- % xanthan gum to mixture 2, additionally containing the ethanol, followed 
by homogenization as above. Different emulsion formulations with varying amounts of 
dispersed phase of 2, 20 and 70 weight-% (E2, E20, E70, respectively) were prepared as 
formulation E. For that purpose, the ratio of buffer pH 7.4 to ethanol of mixture 2 was kept 
constant. Different liposomal dispersions with dispersed phase of 2, 5 and 20 weight-% (LD2, 
LD5 and LD20, respectively) were prepared according to LD. The appropriate amount of 
ethanol was added to achieve a constant ratio of ethanol to buffer in the final formulations. For 
manufacturing ethanol-free formulations, total ethanol of formulations was replaced with buffer 
and NAT 8539® was replaced with the 0.75 fold amount of Phospholipon 80. Nicotinic acid was 
dissolved in buffer, adjusted to a pH of 7.4, added to the combined remaining compounds and 
homogenized as above. All formulations were allowed to equilibrate for at least 24 hours 
before use. The pH of the formulations was measured using a pH-meter 691 and a sensor type 
Porotrode (Metrohm AG, Herisau, Switzerland).  
2.2.2 Ultracentrifugation and chemical analysis of formulations 
The study formulations were fractionated by ultracentrifugation using an ultracentrifuge type 
Centricon T-1075 and a rotor TFT 7013 (Kontron Instruments, Mailand, Italy). Quick-Seal 
centrifuge tubes, 5/8X3 (Beckman Instruments, Palo Alto, USA) were used. CF10 and LD were 
centrifuged for 2 hours, and CF50 and E for 1 hour at 222000-450000 g. The different 
operation times were optimized to fractionate intact structures. Following this treatment, the 
received fractions were carefully isolated by a syringe and analyzed for water, ethanol and the 
drug. 
Water was assayed by Karl-Fischer titration using a KF 701 Titrino (Metrohm AG, Herisau, 
Switzerland) and a one-component reagent CombiTitrant 5. The titer was exactly determined 
with double distilled water prior to every analytical run. EtOH was quantified by an enzymatic 
method (24), based upon spectroscopic determination of accumulated NADH at 340 nm using 
a Perkin Elmer Lambda 20 Spectrometer (Perkin Elmer, Ueberlingen, Germany).  
All model drugs were assayed by HPLC (Hewlett Packard, series 1050, Hewlett Packard, 
Waldborn, Germany). For nicotinic acid, a reversed phase RP-18 column (CC 125/2 
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Lichrospher 100-5 RP-18 ec) was used. The mobile phase consisted of 95% phosphate buffer 
(pH 7.4, β=0.05), containing 5mM tetrabutylammonium hydrogenphosphate and 5% methanol. 
The mobile phase for BTA-Cl quantification consisted of 15% acetonitrile and 85% phosphate 
buffer (pH 3.5, β=0.05) containing 5 mM 1-octanesulfonic acid sodium salt. The same column 
was used as for nicotinic acid. For caffeine, a reversed phase RP-8 column was used (CC 
125/2 Nucleosil 100-5 C8 ec). The mobile phase consisted of 10% acetonitril and 90 % 
phosphate buffer (pH 3.5, β=0.05). Detection was performed UV-spectrophotometrically at 
214, 210 and 255 nm for nicotinic acid, BTA-Cl and caffeine, respectively. The flow rate was 
0.25 ml/min in all cases. The samples were prepared by extraction with at least 100 fold 
amount of buffer pH 7.4, sonification for 5 minutes and filtration through a syringe filter (Titan 2, 
PTFE, 0.2 µm, Sun Sri, NC, USA) prior to injection. 
2.2.3 Particle size measurements 
The z-average of liposomal vesicles and microemulsion droplets was determined by photon 
correlation spectroscopy (PCS) at 25°C using a Malv ern Zetasizer 1000HSa (Malvern 
Instruments Ltd., Malvern, UK). Samples were diluted with filtered aqueous buffer pH 7.4 (0.2 
µm) until counting rates between 100 and 300 KCts/s were reached. For particle size 
determination of microemulsion aggregates, dilution steps from 1/5 to 1/100 were prepared 
with filtered buffer as above. The pinholes for the laser beam were varied to obtain the above 
counting rates for these samples. The mean diameter of emulsion droplets was determined by 
laser diffraction using a Mastersizer S (Malvern Instruments Ltd., Malvern, UK) with a small 
sample unit and a beam lens with 300 mm focal distance. All samples were diluted with 
demineralized water till an obscuration of approx. 20% was reached. 
2.2.4 NMR Diffusion experiments 
Self-diffusion measurements of sodium nicotinate and benzene were performed with the 
bipolar gradient pulse sequence of Wu et al. (25) using a Bruker Avance DRX NMR 
spectrometer operating 600.13 MHz proton frequency. The instrument is equipped with a 5-
mm broadband inverse probe with a shielded z-gradient coil and a GAB gradient amplifier (10 
Ampere, maximum gradient strength 52.5 G/cm). 
All samples contained 5% D2O as lock substance. The diffusion experiments were performed 
at 295 K and the temperature was calibrated using a methanol standard showing accuracy 
within +/- 0.2 K. The gradient strength was calibrated using a Shigemi tube filled with H2O to a 
height of 4.0 mm and imaging this water cylinder (26). The resulting gradient calibration was 
validated by determining the diffusion coefficient of water at 310 K and reproduced the 
literature value within 5%. 
The diffusion experiments were performed by varying the gradient strength between 2% and 
95% of the maximum strength in typically 8 or 16 single experiments while keeping the 
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diffusion times and gradient lengths constant. The entire experiment was then repeated with a 
different diffusion time (100 ms to 500 ms). The intensity decrease of the signal of interest was 
determined and fitted with a Bruker t1/t2 software package suitable for dosy experiments, 
which is included in the XWINNMR software (27). Eq. (1) was used in order to obtain the self-
diffusion coefficients: 
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where, Ig and I0 are the signal intensities in the presence and absence of magnetic field 
gradient pulses with the amplitude G and the duration δ. ∆ Denotes the experimental diffusion 
time, D the diffusion coefficient and Н is given with 4258 Hz/G and depends on the 
gyromagnetic constant for 1H. 
2.2.5 Distribution coefficient determination 
Caffeine, BTA-Cl and sodium nicotinate drug distribution between Mygliol 812N® (triglycerides) 
and the simulated hydrophilic phase of formulations was determined by the shake-flask 
method. Briefly, 1 weight-% of drug was dissolved in aqueous buffer pH 7.4, containing 17 
weight-% of ethanol. This solution was transferred into a separation funnel together with an 
equal amount of triglycerides. The mixture was extensively shaken for 10 min. The two phases 
were allowed to separate for at least one hour before hydrophilic phase was isolated, followed 
by centrifugation for 10 min at 15800 g. Floating triglyceride droplets were removed and the 
hydrophilic phase was analyzed for containing model drug by HPLC (for conditions see 2.2.2). 
Distribution coefficients were calculated as the ratio of the concentration of the triglyceride 
phase, obtained from mass balance, to the measured concentration of the hydrophilic phase. 
2.2.6 Determination of continuous phase drug concentration 
Continuous phase drug concentration was calculated according to Eq. (2). For a multi-phase 
formulation with mass fraction of the continuous phase φcont, this concentration Ccont is given by: 
 
1)1()1( / +−⋅−
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cdcont
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cont K
CC φ   (2) 
 
where, Ctot denotes the overall drug concentration of this formulation and Kd/c the distribution 
coefficient of the drug between the dispersed and the continuous phase. Mass concentrations 
(mg/g) and mass fractions (weight-%/100) were considered. For detailed derivation of Eq. (2), 
see (18). 
In addition, ultrafiltration was applied to determine directly continuous phase drug 
concentrations of the formulations. Centrifugal filter devices (Microcon YM3) with a molecular 
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weight cut-off of 3000 (Millipore, Bedford, MA, USA) were used. The filtrate was analyzed for 
the drug by HPLC after suitable dilution. For HPLC conditions see 2.2.2. 
2.2.7 Permeation experiments 
In all cases, drug permeation was studied in Franz-type diffusion cells with a diffusion surface 
area of 1.7-1.8 cm2 at 32°C across excised full thickness pig ear skin.  The ears of domestic 
pigs were obtained from a local abattoir directly post-mortem. The skin was separated from the 
cartilage tissue by a scalpel, stored in a freezer at –75°C and used within 4 weeks. To avoid 
the effect of individual skin variability, every single permeation experiment was carried out with 
skin of the same pig ear and included all formulations that were compared. The receiver 
medium for the permeation experiments with a volume of 8.5 to 9 ml consisted of an aqueous 
phosphate buffer solution, pH 7.4, β=0.05, additionally containing 0.1% of sodium azide as a 
preservative. Skin integrity was tested by transepidermal water loss (TEWL) measurements 
(Tewameter TM 210,Courage Khazaka electronic GmbH, Germany) after 4 hours of 
equilibration. Then, a practically infinite dose of formulation of at least 1000 mg/cm2 was 
applied onto the skin. The donor compartment was covered with a rubber stopper for 
occlusion. At predetermined time intervals, samples of the receiver medium were collected and 
replaced by fresh buffer. The entire duration of an experiment was 49 hours. The samples 
were analyzed directly for model drug concentration by HPLC (for conditions see section 2.2.2) 
without further treatment except centrifugation for 5 min. at 15800 g. Caffeine permeation 
across a silicon membrane (Perthese®, LP500-3, Bornel, France) was studied with the same 
procedure, but the duration of these experiments was 27.5 hours.  
2.2.8 Drug distribution coefficients between stratum corneum and continuous phase of 
formulations 
Skin sheets with a thickness of about 200 µm were prepared from pig ear skin using a 
pneumatic dermatome (Zimmer, Dover, OH, USA). These sheets were placed in a Petri dish, 
stratum corneum (SC) side up, on filter paper, soaked with 0.125 % trypsin/ 0.5mM EDTA 
solution and incubated at 37°C for 16 hours (21). T hen, the SC was carefully peeled off from 
the underlying epidermal cells and extensively washed with isotonic sodium chloride solution to 
prevent further degradation. The isolated SC sheets were stored in a desiccator over silica gel 
for at least 24 hours, but not longer than two weeks, before use.  
To determine distribution coefficients KS/C between SC and continuous phase of formulations, 
accurately weighted (about 5 mg) pieces of SC were placed into 1.5 ml eppendorf tubes and 1 
g of formulation was added to achieve contact with the SC over its entire area. After an 
equilibration time of 28 hours, the SC pieces were slightly washed with isotonic sodium 
chloride solution for 10 sec. and carefully dabbed with filter paper to remove adhering 
formulation. Drug was extracted from the SC with buffer solution (pH 7.4, β=0.03) by 
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ultrasonication for 2 min (Branson Sonifier 250, output control level 4, duty cycle 40%, Branson 
Ultrasonics Corporation, Danbury, USA). After centrifugation, the supernatant was diluted and 
analyzed for drug concentration by HPLC (for conditions see 2.2.2). SC drug concentrations 
were calculated as mg model drug/dry weight SC in grams. The procedure was optimized for 
trypsin incubation time, formulation removal process after equilibration, range of linearity and 
drug extraction time. 
2.2.9 Data analysis of permeation experiments 
In order to interpret permeation data, it is postulated that continuous phased rug concentration 
of a multi-phase formulation governs permeation kinetics alone. This concentration is given by 
Eq. (2) (see 2.2.6). Assuming the conditions of a perfect sink (receiver concentration 
negligible), an infinite donor reservoir, assuring a constant continuous phase drug 
concentration Ccont, rate limiting membrane (skin) diffusion with the diffusion coefficient D and 
drug distribution between the skin and the continuous phase of the formulation with the 
distribution coefficient KS/C, drug flux J may be described by Fick`s first diffusion law. Drug flux 
J is defined as the amount of drug permeated through the skin per unit time and unit area and 
is given by: 
 
contCPJ ⋅=      (3) 
 
with P as the permeability coefficient (cm/s) with h as thickness of the diffusion rate limiting 
membrane 
 
h
KDP CS /⋅=     (4) 
 
Combining Eqs. (2) and (3) gives a term to calculate permeability coefficients considering 
continuous phase drug concentration: 
 
tot
cdcont
C
KJP 1)1()1( / +−⋅−⋅= φ   (5) 
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3 Results  
3.1 Formulation characterization 
3.1.1 Ultracentrifugation experiments 
Ultracentrifugation was applied to fractionate the intact structures of the formulations as 
previously demonstrated as good methodology to investigate multi-phase dermatological 
formulations by separation of the comprising dispersed phase structures (18). Independently of 
the included model drugs, the study formulations yielded the following fractions: E a white, 
turbid fraction on top (fraction A) and a clear fraction in the bottom (fraction B). LD gave a clear 
fraction on top (fraction B) and a brown turbid fraction (fraction C) in the bottom. CF10 gave 
three fractions that appeared comparable, from top to bottom, to the fractions A, B and C, but 
the clear fraction B was little yellowish. CF50 gave only two factions, a fraction comparable to 
fraction A and a deep yellow, but clear fraction B in the bottom. These observations agree well 
with previous work where the study formulations which contained sodium nicotinate were 
characterized very detailed by complete chemical component analysis of all received fractions, 
freeze fracture scanning electron microscopy and particle size measurements (18). That 
investigation demonstrated that the fractions A and C contained emulsion droplets and 
liposomes, respectively. The deep yellow, clear fraction B of CF50 consisted of 13 weight-% 
phospholipids, 13 weight-% triglycerides, 10 weight-% polysorbate 20 and hydrophilic phase 
(13 weight-% ethanol and 51 weight-% buffer pH 7.4). This composition and further 
characteristics such as rheological behavior and spontaneous formation of the system strongly 
indicated a microemulsion structure. The clear fraction B of CF10 included an overall sum of 4 
weight% of phospholpids, triglycerides and polysorbate 20 in a roughly comparable ratio to the 
microemulsion found within CF50. Hence, for CF10, a coexistence of liposomes, emulsion 
droplets and microemulsion aggregates was assumed. 
In addition to the formulations that included the sodium nicotinate, all identical fractions 
received from the formulations that contained BTA-Cl and caffeine were analyzed for water 
and ethanol. Fig.1 compares all these results. A good agreement for the analyzed components 
is observed, as demonstrated by the comparable concentration bars, not depending on the 
incorporated drug. Furthermore, the ratio of water to ethanol is equal in each fraction and to 
the ratio of these components contained in the corresponding complete formulation, indicating 
that the sum of water and ethanol amounts to the continuous hydrophilic phase, independently 
of dispersed structure and incorporated model drug. 
3.1.2 Particle sizes of liopsomes and emulsion droplets 
The diameters of liposomes and emulsion droplets of the formulations are shown in Fig.2. 
These structures are of comparable size, independently of the included model drug. A 
tendency of smaller emulsion droplets within the formulations with big amount of dispersed 
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phase (CF50 and E), compared to CF10, and of smaller liposomes within CF10, compared to 
the liposomes of LD, is obvious. This is in good agreement with the previous work and 
discussed there (18). 
3.1.3 Microemulsion characterisation 
NMR diffusion experiments and particle size measurements using PCS were carried out in 
order to verify the presence of the microemulsion structure within CF50 and to determine if the 
oil phase is continuous or droplet like. Direct PCS measurements of the fraction B of CF50, 
comprising the microemulsion, was not possible because of the big amount of dispersed 
phase, which required dilution for that purpose. Independently of different dilution steps and 
the included model drug, the measured diameters were in between 20 and 24 nm and the 
polydispersity index (PI) was almost always between 0.1 and 0.2, indicating a rather narrow 
size distribution of the analyzed structures (Table 2). 
 NMR diffusion measurements within this assumed microemulsion system gave self-diffusion 
coefficients for sodium nicotinate only twice less than within the gel (Table 3). The sodium 
nicotinate was used for that examination to obtain isolated 1H NMR signal peaks and had, for 
this purpose, the function of a hydrophilic marker, because it distributed completely into the 
hydrophilic phase of formulations (see 3.1.4). However, the incorporation of the lipophilic 
marker benzene into this microemulsion that was isolated from a drug-free formulation CF50 
gave a self-diffusion coefficient of 3.5E-11 m2/s. That is about tenfold less than benzene self-
diffusion within triglycerides (2.06E-10 m2/s) which were assumed to be representative for a 
lipophilic bulk. 
In case of fraction B of CF10, the relatively small amount of dispersed phase facilitated 
undiluted PCS inspection and gave diameters slightly larger as measured for the 
microemulsion structures within CF50, but with a broader variability, expressed as larger 
values for PI (Table 2).  
3.1.4 Continuous phase drug concentrations and self-diffusion coefficients 
According to the proposed concept in order to investigate drug delivery potential of multi-phase 
dermatological vehicles (see 2.2.9), an exact determination of continuous phase drug 
concentration is a crucial parameter. Independently of the existing microstructures and of the 
incorporated model drug, the continuous phase consisted of buffer and the total amount of 
ethanol in case of the study formulations (see 3.1.1). Drug distribution between the 
triglycerides and the simulated hydrophilic phase was determined by the shake-flask method. 
This method indicated no distribution of the charged substances (sodium nicotinate and BTA-
Cl) into bulk triglycerides, while the caffeine gave a distribution coefficient of 0.2 between 
triglycerides and hydrophilic phase.  
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Hence, continuous phase drug concentrations were calculated considering the phase ratios 
from dispersed to continuous phases given by the formulation composition (Table 1) using Eq. 
(2). For that purpose, Kd/c was approximated with zero, only for the caffeine a value of 0.2 was 
applied in case of triglycerides comprising formulations. Distribution into liposomes and other 
phospholipid based structures was neglected because of the relatively low amounts of 
phospholipids within the formulations, compared to triglycerides. These calculated 
concentrations are given in Table 4. Beside this theoretical calculation, ultrafiltration 
experiments were performed in order to measure continuous phase drug concentrations. The 
results are also given in Table 4 and agree well with the calculated values. 
Furthermore, drug concentrations of the fractions B of LD and E following ultracentrifugation 
were used to estimate the distribution of the drugs between intact formulation structures. 
Previous work demonstrated that fraction B of E contained about 5 weight-% of polysorbate 
20, but no triglycerides, and this fraction of LD was found to be free of phospholipids (18). 
Again, a slight distribution of caffeine into triglycerides was indicated by the caffeine 
concentration of fraction B of E, while sodium nicotinate and BTA-Cl concentrations in the 
fraction B of E and LD indicated negligible distribution into emulsion droplets and liposomes, 
supporting the above results (Table 4). Hence, the calculated continuous phase drug 
concentrations given in Table 4 were applied for further investigations. 
The molecular mobility of a drug within a formulation is reportedly a further aspect that may 
contribute to drug delivery (3,4). Thus, we performed NMR diffusion experiments in order to 
determine self-diffusion coefficients for sodium nicotinate within all study formulations. The 
results are given in Table 3. The molecular mobility within the formulations was different and 
decreased in the order gel > CF10 > fraction B of E> E> LD = fraction B (microemulsion) of 
CF50. The sodium nicotinate gave high resulated 1H NMR spectra with narrow signal peaks. 
Only for E, broad signal peaks were obtained, for what the reason was not further investigated. 
For CF50, the diffusion coefficent within the isolated fraction B, comprising the microemulsion, 
was considered (see 3.1.3). 
3.2 Permeation experiments 
3.2.1 Permeation across a silicon membrane and pig ear skin 
Fig.3 shows the permeation pattern of caffeine across a silicon membrane (Fig.3 a.) and 
across pig ear skin (Fig.3 b.). The permeation profile of caffeine for CF50 across the silicon 
membrane agrees well with the caffeine permeation profile for E. Likewise CF10, LD and the 
gel gave identical permeation profiles, compared among them, while the drug flux was about 
two times less for these three formulations, compared to CF50 and E. Permeation across pig 
ear skin, however, differed from permeation across the silicon membrane (Fig.3 b.).  
Eq. (5) was applied to calculate permeability coefficients for BTA-Cl, sodium nicotinate and 
caffeine permeation for the study-formulations across pig ear skin and for caffeine across the 
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silicon membrane (Table 5). Caffeine permeability coefficients across the silicon membrane 
are equal for all formulations, indicating that continuous phase drug concentration governed 
this permeation alone. However, permeability coefficients across skin are different for the 
formulations, for caffeine, BTA-Cl and for sodium nicotinate. To interpret this finding, the 
permeability coefficients across skin for all multi-phase formulations were compared to the 
permeability coefficient for the gel. In addition, permeability coefficients obtained from CF50 
and CF10 were compared to those obtained from the formulations that contained comparable 
continuous phase drug concentrations, E and LD, respectively. A significant enhancement (t-
test, double sided, p< 0.1) compared to the gel was found for sodium nicotinate permeation 
from CF50 and CF10. However, formulations that were prepared without ethanol gave sodium 
nicotinate permeability coefficients in the same order of magnitude for all formulations and for 
a purely aqueous gel (Table 6). Compared to LD, all drugs showed significantly increased 
permeation from CF10 (t-test, double sided, p< 0.1). Likewise caffeine and sodium nicotinate 
permeation from CF50 was significantly increased (t-test, double sided, p< 0.1) compared to E. 
In addition to this permeation enhancement, a tendency of decreasing permeation for BTA-Cl 
from CF50, E and LD and for caffeine from LD and E was observed, compared to permeation 
from the gel (Table 5). This effect was significant for caffeine permeation from E (t-test, double 
sided, p< 0.1). Thus, further permeation experiments with purely emulsions which comprised 
variable amounts of dispersed phase of 2, 20 and 70 weight-% (E2, E20 and E70, 
respectively) were performed with all three model drugs (Table 5). Respective continuous 
phase drug concentration was tested using ultrafiltration and agreed with calculated 
concentrations (data not shown). Caffeine and BTA-Cl permeation decreased with increasing 
dispersed phase ratio of the emulsions, but not sodium nicotinate permeation.  
3.2.2 Drug distribution into and diffusion within stratum corneum 
In order to gain a deeper understanding of the dependence of differences in drug permeation 
on the physicochemical structure of the formulation, drug distribution coefficients between the 
stratum corneum (SC) and, according to the proposed concept, continuous phase of the 
formulations (KS/C) were determined. Table 7 shows that the study formulations had an effect 
on the distribution of the model drugs into the SC. For all drugs, drug distribution into the SC 
was favored from the gel, compared to the study formulations. Closer examination suggested 
that drug distribution into the SC from the formulations with big amount of dispersed phase 
(CF50 and E) was smaller, compared to the formulations that contained lesser amount of 
dispersed phase (CF10 and LD). Distribution coefficients between the SC and the emulsion 
formulations with variable amounts of dispersed phase (E2, E20 and E70) were also 
determined for BTA-Cl and caffeine. A tendency of decreasing distribution into the skin with 
increasing amount of dispersed phase of these emulsions is obvious (Table 7). Equal results 
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were obtained for different liposomal dispersions, which contained variable amounts of 
dispersed phase of 2, 5 and 20 weight-% (LD2, LD5 and LD20, respectively) (data also given 
in Table 7). 
Drug diffusion coefficients within the SC were calculated taking into account the permeability 
coefficients (Table 5) and the according KS/C values given in Table 7 using Eq. (4). For that 
purpose, the mean of KS/C for a specific drug and a specific formulation was applied to every 
single permeation experiment. The calculated diffusion coefficients are shown in Fig.4. The 
diffusion coefficients following permeation from CF10 and CF50 were significantly increased 
compared to the gel for all model drugs (t-test, double sided, p< 0.1). Comparable diffusion 
coefficients in the skin for the drugs following permeation from LD, E and the gel further 
indicated that the decrease in drug permeation (see 3.2.1) was a result of decreased 
distribution coefficients KS/C alone. 
The same calculation was carried out with caffeine and BTA-Cl permeation data obtained from 
E2, E20 and E70 (Table 5) and the according KS/C values (Table 7). This inspection gave 
strongly equal diffusion coefficients within the stratum corneum and values in the same order 
of magnitude to those obtained from formulation E (Fig.5). 
 
4 Discussion 
Permeation across and distribution into the skin of hydrophilic model drugs from different multi-
phasic dermatological o/w formulations was studied in order to understand the role of their 
microstructure on these processes. For that purpose, continuous phase drug concentrations of 
the formulations were considered, according to a proposed concept which postulates that this 
concentration is the only parameter governing permeation kinetics. 
Independently of the included model drug, the used drug concentration did not cause major 
structural alterations of the study formulations, as attested by ultracentrifugation experiments 
and particle size measurements of liposomes and emulsion droplets. Comparable water and 
ethanol content of the received fractions following ultracentrifugation confirmed this finding and 
further indicated that the ratios form dispersed to continuous phases of the formulations were 
not influenced by the different model drugs. Hence, the used criteria were considered to be 
conclusive to apply the detailed structural investigation that was performed with the sodium 
nicotinate containing formulations previously to the formulations that contained caffeine and 
BTA-Cl (18).  
Microemulsion structures were identified beside emulsion droplets within CF50 and in addition 
to coexisting emulsion droplets and liposomes within CF10. NMR diffusion experiments could 
demonstrate that the isolated microemulsion from CF50 comprised droplet-like lipophilic 
structures in a hydrophilic continuous environment. While conductivity measurements already 
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indicated hydrophilic continuous phase previously (18), it was not clear whether lipophilic 
phase is continuous or droplet like. A tenfold less benzene self-diffusion coefficient within this 
microemulsion, compared to benzene self-diffusion within triglycerides, however, strongly 
indicated restricted diffusion and, hence, a droplet-like lipophilic structure. In case of a 
bicontinuous structure, benzene self-diffusion within the microemulsion and the bulk lipophilic 
phase would be in the same order of magnitude (4). This, however, was true for sodium 
nicotinate self-diffusion within this system and the gel, supporting the previous finding of 
hydrophilic continuous phase (Table 3). The benzene and the sodium nicotinate were chosen 
for this examination because they gave high resulated 1H NMR spectra, not overlapping with 
the signals of other formulation compounds. The droplet-like character of the microemulsion 
aggregates was further supported by PCS measurements, which gave a droplet size of in 
between 20 and 24 nm, not depending on different dilution steps (Table 2). Additionally, the 
comparable particle size for the microemulsion structures of CF50 containing the different 
model drugs also supported the conclusions drawn above of the independence of the 
microstructure on the incorporated model drug (Table 2). The relatively small polydispersity 
index (PI) is a further evidence for a spontaneously arising microemulsion with defined, stable 
structure, because no efforts have been made to obtain such a narrow size distribution. The 
slightly larger particle sizes of the microemulsion aggregates measured for fraction B of CF10, 
compared to the microemulsion aggregates of CF50, were supposed to be due to some not 
completely separated coarse particles during ultracentrifugation, which simulate a larger z-
average for the complete sample. This explanation is further supported by the values for the PI 
of the single experiments. The smaller the PI, the more agreed the particle size of these 
microemulsion aggregates for fraction B of CF10 with the data obtained from CF50 (Table 2). 
Hence, an equal structure for the microemulsion systems found within CF10 and CF50 is 
assumed and it is supposed that these structures may arise spontaneously beside other 
dispersed structures within multi-component formulations which consist of polysorbate 20, 
triglycerides, phospholipids and hydrophilic phase. 
Independently of the microstructures, Eq. (2) was applied to calculate continuous phase drug 
concentrations of all model drugs for all study-formulations. These calculated concentrations 
were in good agreement with the continuous phase drug concentrations obtained from 
ultrafiltration experiments (Table 4). This is evidence for the validity of Eq. (2) and, importantly, 
further points out that no obvious association of the model drugs with the surface of the 
dispersed structures took place. The theoretical continuous phase drug concentrations derived 
from Eq. (2) consider distribution coefficients between dispersed and continuous phase 
structures obtained from the shake flask method, which represents the solubility properties of 
the drug in the system. Ultrafiltration, however, provides a methodology that considers the 
whole formulations, and, hence, may also reveal associations of the drugs with dispersed 
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formulation structures. Furthermore, the drug concentrations within fraction B of CF50, 
comprising the microemulsion, compared to the continuous phase drug concentrations 
obtained from ultrafiltration of CF50 (Table 4) indicated that this methodology can separate the 
microemulsion aggregates from the continuous phase, which is further supported by obtained 
colorless filtrates in all cases. This is an important result because the microemulsion 
aggregates were considered as dispersed structures in this work. Drug concentrations within 
fractions B of LD and E also confirmed the findings of the ultrafiltration experiments. In addition 
to all these results, a coulomb association of the sodium nicotinate with charged surfaces of 
dispersed phase structures, for example liposomes or microemulsion aggregates, would likely 
yield broad NMR signal peaks of the sodium nicotinate. Consequently, the continuous phase 
drug concentrations calculated with Eq. (2) were used for the interpretation of permeation and 
distribution data (Table 4). 
Permeation experiments across a synthetic lipophilic barrier and across excised skin provide 
an easy methodology to discriminate between formulation effects related to physicochemical 
parameters and those correlated to biological factors on skin barrier function (5). Equal 
permeability coefficients for caffeine permeation across a silicon membrane, calculated with 
Eq. (5), demonstrated that the observed increased caffeine flux from CF50 and E (Fig.3 a.) 
compared to LD, CF10 and the gel, was governed by continuous phase drug concentrations 
alone (Table 5). This is evidence for the validity of the proposed concept. These experiments 
were performed with the caffeine because the silicon membrane was permeable for that 
substance. 
Caffeine permeation profile across excised pig ear skin, however, was different compared to 
the permeation profile across the silicon membrane (Fig.3 a.,b.). Permeability coefficients for 
all formulations across skin, calculated with Eq. (5), were different, not only for caffeine, but 
also for BTA-Cl and sodium nicotinate (Table 5). This indicated further effects that had impact 
on skin permeation, in addition to continuous phase drug concentration. An enhanced 
permeation of the sodium nicotinate from CF10 and CF50, compared to LD, E and the gel was 
obvious. Sodium nicotinate permeation was further studied from comparable formulations to 
those given in Table 1, but designed without ethanol in order to investigate a possible 
synergism with the alcohol, taking into account the literature (6,7,9). Comparable permeability 
coefficients were obtained for all formulations, strongly indicating a synergism of ethanol and 
dispersed formulation structures of CF10 and CF50 to the observed permeation enhancement 
(Table 6). This also confirms the previous work where ethanol was removed from the 
formulations by evaporation and continuous phase drug concentration alone could explain the 
permeation kinetic (18). For caffeine and BTA-Cl, the interpretation of the different permeability 
coefficients was not that clear, because, somewhat unexpected, also smaller permeability 
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coefficients were calculated, compared to the gel, indicating also permeation retarding effects 
due to dispersed formulation structures (Table 5). 
Taking into account Eqs. (3) and (4), steady state drug permeation may be affected by (I) 
altered drug diffusion coefficient in the skin, (II) altered drug distribution coefficient between the 
skin and the vehicle or differences in drug concentration (28,29). In order to explain the 
observed differences of the permeability coefficients, drug distribution coefficients between 
stratum corneum and the study formulations KS/C were determined, considering continuous 
phase drug concentrations (Table 7). These data and the according permeability coefficients 
(Table 5) were used to calculate diffusion coefficients in the stratum corneum using Eq. (4), a 
constant thickness for stratum corneum of 15 µm assumed. The stratum corneum was 
identified as site of action for the formulation effects by additional permeation experiments 
across stripped skin, which provided negligible diffusional resistance for all model drugs, 
compared to intact skin (data not shown). The calculated diffusion coefficients within the 
stratum corneum finally attested the complex formulations CF50 and CF10 properties to 
enhance drug diffusion coefficients within the stratum corneum for all model drugs (Fig.4). 
These two formulations were the only formulations including microemulsion structures beside 
emulsion droplets and liposomes, strongly indicating that the enhancing properties of CF10 
and CF50 were due to an interaction between these microemulsion structures and the stratum 
corneum, because liposomes and emulsion droplets were also formed within LD and E, 
respectively. This assumption was supported by further sodium nicotinate permeation 
experiments that were performed with the isolated fractions B, comprising the microemulsion 
structures, referred to as MeCF50 and MeCF10 (Table 5), which gave comparable 
permeability coefficients to the intact formulations CF50 and CF10. Several publications report 
on improved transdermal or dermal drug delivery from microemulsion systems (11,12,13,14). 
Generally, two basic trends are observable from the reported studies that may contribute to the 
favorable drug delivery properties: high drug load capacity and penetration enhancer effects. 
The latter is true for the microemulsion structures identified in the study formulations, because 
the application of the described concept considers the available concentration, i.e. continuous 
phase drug concentration. The permeation enhancing effect is not only a result of the ethanol 
included in the formulation (28), as attested by taking into account ethanol containing 
references. The observed synergism with the ethanol may be due to a primary action of the 
alcohol with the stratum corneum, facilitating further interaction of the microemulsion structures 
with the stratum corneum lipids. Other authors proposed also such a synergism (6,7,9). In 
contrast to these publications, however, we could not confirm enhancing properties of 
conventional liposomal vesicles. Furthermore, usually extensive efforts are made for 
discovering pharmaceutical acceptable microemulsions, for example the construction of more 
dimensional phase diagrams (11,30). The microemulsions discussed in this work, however, 
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arise spontaneously beside other structures and, thus, provide a readily available tool to 
improve drug skin permeation. 
The diffusion coefficients given in Figure 4 may also explain decreased permeation of the 
model drugs from some study formulations, compared to the gel. Such effects were most 
obvious for BTA-Cl and caffeine for E and LD (Table 5). Comparable diffusion coefficients of 
the model drugs within the skin, following permeation from LD, E and the gel, demonstrated 
that this decreased permeation was caused by decreased solubility of the model drug within 
the stratum corneum, expressed as smaller values for KS/C (Table 7, Fig.4). Caffeine and BTA-
Cl permeation from different emulsions, which were designed in order to comprise widely 
varying amounts of dispersed phase, confirmed this finding and further indicated a 
dependency of the observed permeation retarding effect on the phase ratio of dispersed to 
continuous phase of the formulations (Table 7, Fig.5). Decrease in KS/C with rising amount of 
dispersed phase was also observed for different liposomal dispersions, comprising variable 
amounts of phospholipids (Table 7). The effects that lead to decreasing values for KS/C were 
most likely due to an interaction of the dispersed formulation structures with the stratum 
corneum, rather than a simple mechanical effect on the skin surface, as sometimes reported 
for such permeation retarding effects (31). Caffeine permeation experiments across the silicon 
membrane and the consideration of dry weight of stratum corneum for the calculation of KS/C 
may explain this. First, no retarded permeation was found for caffeine across the silicon 
membrane for E and LD, and secondly, KS/C was obtained from drug concentrations within the 
stratum corneum, equilibrated with the respective formulation. Thus, the situation of equilibrium 
and the consideration of dry weight of stratum corneum include a constant drug concentration 
within the stratum corneum if its solubility properties are not affected, independently of a 
possible protective film on its surface formed by dispersed formulation structures. It is worth 
mentioning that diffusion coefficients calculated with Eq. (4) gave lesser values, compared to 
corresponding true values in the hydrated state of stratum corneum because of the 
consideration of its dry weight. However, this yielded less variation of the results, compared to 
weighting of hydrated stratum corneum after equilibration. 
In the situation of transdermal drug delivery from a multi-phase dermatological formulation, two 
diffusion-related processes take place: the discussed drug diffusion within the skin and drug 
diffusion within the formulation to the skin. Thus, self-diffusion of the sodium nicotinate within 
the study formulations was measured by NMR diffusion experiments (Table 3) and compared 
to the calculated diffusion coefficients within the stratum corneum (Fig.4). As mentioned above, 
the diffusion coefficients shown in Fig. 4 are smaller, compared to true values in the hydrated 
state of stratum corneum, taking into account Eq. (4). However, the values may be corrected 
by the factor 2.75, because fully hydrated stratum corneum binds the 2.75 fold amount of water 
of its dry weight (32). The corrected diffusion coefficients within the stratum corneum are at 
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least two orders of magnitude smaller (data not shown, but easy to estimate taking in account 
Fig. 4), compared to the sodium nicotinate diffusion coefficients in the formulations (Table 3). 
This finally indicates that diffusion in the skin dominates permeation kinetics, confirming a 
published work where diclofenac permeation from different phospholipid-based formulations 
was investigated (33). The sodium nicotinate was chosen for the NMR diffusion studies 
because its enhanced permeation from CF10 and CF50 was most obvious. The observed 
moderate difference of the self-diffusion coefficients (Table 3) for the study formulations was 
very likely due to unequal sterically hindered diffusion. According to the equation Dtr 62 =∆ , 
the average diffusion way r of a molecule, three-dimensional diffusion assumed, may be 
calculated considering the effective diffusion time t and the respective diffusion coefficient D. 
For sodium nicotinate, this diffusion way exceeded the size of the dispersed structures by far 
(Fig.2). For example, in 250 ms, the calculated value for r within the gel was 29 µm, and within 
CF50, this average diffusion way was about 18 µm. Thus, the relatively long diffusion way 
during the measured effective diffusion time of 250 ms includes that the sodium nicotinate had 
to diffuse around dispersed structures, which become more important when they are small 
and, hence, closer packed (liposomes within LD and microemulsion aggregates within CF50). 
If micellar polysorbate 20 is also considered as diffusional barrier, this also explains the similar 
sodium nicotinate diffusion within E as within the isolated fraction B of E, because this fraction 
contained about 5 weight-% of micellar polysorbate 20 beside buffer and ethanol (see 3.1.4).  
To conclude, the proposed continuous phase drug concentration concept allows delineating 
the regulation of skin permeation by the formulation as a result of physicochemical parameters, 
including drug distribution among distinct phases of formulation, and/or as a result of affecting 
skin permeability of the drug due to a vehicle-stratum corneum interaction. Thus, this concept 
valuably contributes to an effective development of dermatological formulations as well as to 
successfully drug delivery in clinical situations. Furthermore, the microemulsions that were 
identified within CF10 and CF50 provide a predictive tool to improve transdermal drug delivery, 
because they consist of non-irritant components and arise spontaneously within multi-
component formulations. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Analyzed amounts of water and ethanol within fractions received from 
ultracentrifugation. One diagram represents one formulation. Equal bars for one fraction 
denote water or ethanol content within this fraction obtained from the formulation that 
contained, from left to right, sodium nicotinate, BTA-Cl or caffeine as model drug. Error bars 
denote SEM (n=3-4) 
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b. 
 
Figure 2 Diameters of emulsion droplets in µm (a.) and liposomes in nm (b.) of the 
formulations which contained the different model drugs. Error bars denote SEM, n=3-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liposome sizes
0.00
50.00
100.00
150.00
200.00
250.00
300.00
350.00
CF10 LD
M
ea
n
-
di
am
et
er
 
(nm
)
Sodium nicotinate
BTA-Cl
Caffeine
Emulsion droplet sizes
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
CF10 CF50 E
M
e
a
n
-
di
a
m
e
te
r 
( µµ µµ
m
)
Sodium nicotinate
BTA-Cl
Caffeine
  
Original Publications 
   
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. 
 
Figure 3 Permeation profile of caffeine following application of the study formulations across a 
silicone membrane (a.) and across excised pig ear skin (b.). For simplicity, error bars are not 
shown  
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Figure 4 Diffusion coefficients within the stratum corneum of the model drugs following 
permeation from the study formulations. Error bars denote SEM, n=4-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Diffusion coefficients of caffeine and BTA-Cl within the stratum corneum following 
permeation from different emulsion formulations with variable amounts of dispersed phase of 
2, 20 and 70 weight-% (E2, E20 and E70, respectively). Error bars denote SEM, n=3-6 
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Tables 
 
Table 1 
Composition of the study formulations (in weight-%) 
 CF 10a CF 50b Ec LDd Gele 
Model drug 1.0 1.0 1.0 1.0 1.0 
Aqueous buffer 
pH 7.4 
73.85 34.9 36.92 74.25 81 
Ethanol 96% 14.1 6.6 9.98 11.82 17.5 
Mygliol 812N® 6.75 36.0 47.9   
Polysorbate 20 1.35 8 4.0   
NAT 8539 2.4 13.38  12.33  
Tocopherol 0.05 0.1  0.1  
Xanthan gum 0.5 0.20 0.20 0.5 0.5 
aComplex formulation with 10 weight-% dispersed phase, bComplex formulation with 50 
weight-% dispersed phase, cEmulsion with 50 weight-% dispersed phase, dLiposomal 
dispersion with 10 weight-% dispersed phase, eEthanolic gel. The model drug is sodium 
nicotinate, expressed as nicotinic acid, BTA-Cl or caffeine. 
 
 
 
 
Table 2 Diameters of microemulsion aggregates included in CF10 and CF50 
Fraction B 
of CF50 
      
Included 
model drug 
Sodium 
nicotinate 
 BTA-Cl  Caffeine  
Dilution z-average PI z-average PI z-average  PI 
1/5 23.9 0.162 20.7 0.091 23.5 0.27 
1/10 23.7 0.112 21.5 0.091 22.1 0.151 
1/20 23.4 0.088 21.8 0.09 23.8 0.187 
1/100 22.6 0.130 21.3 0.075 23.0 0.153 
Fraction B 
of CF10 
      
Single 
experiments 
      
1 46.4 0.527 29.4 0.288 32.2 0.246 
2 29.1 0.16 29.9 0.23 32.1 0.419 
3 27.8 0.153 44.4 0.471 26.5 0.22 
Values denote nm and PI stands for polydispersity index. Microemulsion aggregates 
comprised within fraction B separated from CF10 were inspected undiluted and the numbers1-
3 denote single inspections of different samples 
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Table 3 Sodium nicotinate self-diffusion coefficients within the formulations 
 CF10 CF50 LD E Gel 
Diffusion 
Coefficients 
4.30E-10 a2.18E-10 2.19E-10 2.49E-10 
b3.30E-10  
5.66E-10 
Values obtained from NMR diffusion experiments, effective diffusion time 250 ms. aDenotes 
the self-diffusion coefficient in the isolated fraction B (microemulsion) of CF50, bdenotes the 
self-diffusion coefficient within the isolated fraction B of E. All values in m2/s 
 
 
 
 
Table 4 Ultrafiltration, ultracentrifugation and continuous phase drug concentrations  
Formulation Model Drug Calculated 
concentrationa 
Measured 
concentration 
UFb 
Measured 
concentration 
fraction B, UZc 
CF50 Sodium 
nicotinate 
22.22 26.96±3.32 14.54±0.073 
 BTA-Cl 22.22 20.16±1.88 14.73±0.043 
 Caffeine 18.52 17.55±4.76 13.04±0.048 
CF10 Sodium 
nicotinate 
11.18 11.03±0.37 11.23±0.028 
 BTA-Cl 11.18 10.40±0.41 11.03±0.084 
 Caffeine 10.91 11.06±1.40 11.24±0.0071 
LD Sodium 
nicotinate 
11.11 10.60±0.93 11.90±0.26 
 BTA-Cl 11.11 10.28±1.51 10.43±0.76 
 Caffeine 11.11 11.08±0.94 11.21±0.085 
E Sodium 
nicotinate 
21.27 23.11±0.53 20.75±0.23 
 BTA-Cl 21.27 21.15±1.14 20.41±0.38 
 Caffeine 17.36 17.42±1.42 18.18±0.15 
aCalculated concentrations with Eq. (2). bConcentrations resulting from ultrafiltration 
experiments. cConcentrations of received fractions B following ultracentrifugation of LD and E. 
Sodium nicotinate is expressed as nicotinic acid. All drug concentrations in mg/g ± SD, n=3-4 
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Table 5 Permeability coefficients  
 Sodium nicotinate BTA-Cl Caffeine Caffeine a.s.a 
CF50 3.03E-07±2.38E-08 2.42E-07±2.18E-08 3.10E-07±5.01E-08 9.88E-08±1.21E-08 
CF10 3.56E-07±3.73E-08 4.57E-07±3.05E-08 4.25E-07±3.17E-08 8.36E-08±9.22E-09 
LD 1.43E-07±1.24E-08 3.12E-07±3.61E-08 2.14E-07±4.46E-08 8.68E-08±8.68E-09 
E 1.55E-07±1.20E-08 2.44E-07±2.08E-08 1.78E-07±8.20E-09 9.81E-08±1.06E-08 
Gel 1.44E-07±8.56E-09 3.81E-07±1.70E-07 3.35E-07±4.15E-08 9.40E-08±8.58E-09 
MeCF50 2.60E-07±1.21E-08 2.04E-07±1.01E-08 2.63E-07±1.75E-08  
MeCF10 3.87E-07±5.21E-08 4.36E-07±5.39E-08 3.00E-07±2.82E-08  
E2 1.30E-07±3.25E-08 3.12E-07±5.44E-08 1.98E-07±5.13E-08  
E20 9.11E-08±2.68E-08 2.44E-07±1.63E-08 1.72E-07±1.39E-08  
E70 1.16E-07±3.93E-08 2.04E-07±3.90E-08 1.36E-07±1.54E-08  
Bold values correspond to the study formulations given in Table 1. MeCF50 and MeCF10 
denote the microemulsion structures isolated from CF50 and CF10, respectively. Caffeine a.s. 
denotes permeability coefficients for caffeine across a silicon membrane. E2, E20 and E70 are 
different emulsion formulations with variable amounts of dispersed phase of 2, 20 and 70 
weight-%, respectively. All values in cm/s ± SEM, n=4-6, an=3 
 
 
 
 
Table 6 Sodium nicotinate permeability coefficients for ethanol free formulations 
 CF50a CF10a LDa Ea Gela 
P 1.01E-07± 
1.54E-08 
1.18E-07± 
1.43E-08 
1.04E-07± 
2.43E-08 
7.42E-08± 
1.46E-08 
8.32E-08± 
5.41E-09 
aDenotes the study formulations given in Table 1, but manufactured without ethanol. All values 
in cm/s ± SEM, n=3 
 
 
 
 
Table 7 Drug distribution coefficients KS/C between stratum corneum and continuous phase of 
formulations 
 
 Sodium nicotinate BTA-Cl Caffeine 
CF50 0.32 ± 0.076 0.61± 0.020 0.56± 0.089 
CF10 0.52 ± 0.050 1.06± 0.076 0.99± 0.15 
LD 0.76 ± 0.18 1.40± 0.081 1.12± 0.15 
E 0.53 ± 0.10 0.96± 0.055 0.96± 0.14 
Gel 0.96 ± 0.11 1.75± 0.12 2.31± 0.20 
E2  1.77±0.10 1.79±0.12 
E20  1.45±0.23 1.54±0.16 
E70  1.04±0.096 1.13±0.082 
LD2  1.78±0.044 1.99±0.18 
LD5  1.51±0.073 1.23±0.16 
LD20  0.92±0.063 1.03±0.095 
Bold values correspond to the study formulations given in Table 1. E2, E20 and E70 denote 
different emulsion formulations with variable amounts of dispersed phase of 2, 20 and 70 
weight-%, respectively. LD2, LD5 and LD20 denote different liposomal dispersions with 
variable amounts of dispersed phase of 2,5 and 20 weight-%, respectively. All values denote 
mean ± SEM. n=4-7  
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D.2 How the alteration of multi-phase dermatological formulations following 
application affects skin permeation of a hydrophilic model drug 
 
Abstract 
The goal of this work was to investigate the influence of multi-phase dermatological o/w 
formulations on in-vitro drug permeation across pig ear skin taking especially into 
consideration alterations these formulations undergo due to evaporation of volatile 
components following non-occlusive application. A concept is proposed that postulates 
changing continuous phase drug concentration during application as the only parameter 
governing permeation kinetics. Sodium nicotinate was used as model drug and the studied o/w 
formulations consisted of phospholipids, triglycerides, emulsifier, ethanol and water in 
proportions covering a wide range of values and phase ratios from dispersed to continuous 
phase. Depending on the individual composition, coexisting dispersed phase structures, such 
as liposomes, emulsion droplets and microemulsions were formed, as attested by 
ultracentrifugation experiments, chemical component analysis, scanning electron microscopy 
and particle size measurements. Evaporation of volatile componets during application yielded 
phase transitions, including vesicle to microemulsion, phase inversion from o/w to w/o and 
drug precipitation. Independently of structural changes, continuous phase drug concentration 
could quantitatively describe permeation kinetics without the need to consider formulation 
effects on skin barrier function. Hence, the proposed concept provides a predictive tool to 
describe quantitatively drug permeation from non-occlusively applied multi-phase 
dermatological formulations.  
 
1 Introduction 
In clinical practice, drugs are incorporated in a vehicle in order to be applied to the skin for 
topical or systemic therapy (1). Vehicles typically consist of several components that are often 
not mutually miscible, thus forming separate phases. The phases of such a formulation are 
intermixed, producing macroscopically homogeneous systems, while the structures on the 
microscopic level, however, may be completely different. It is meanwhile widely acknowledged 
that such formulations, which are conceived as drug delivery vehicles, regulate transdermal 
permeation. This regulation may take place based on physicochemical principles such as 
diffusion and partitioning of the active ingredient and/or by an interaction with the skin, 
affecting its permeability of the drug. For example, liposomal vesicles (2,3) or microemulsions 
(4,5,6) have been credited with enhancing skin permeation of active ingredient(s). Reviews 
from Kreilgard (7) and Bouwstra and Honeywell-Nguyen (8) give good overviews about the 
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range of publications that report on dermal and transdermal drug delivery from microemulsions 
and liposomes, respectively. 
Another crucial aspect that is, however, not considered to any great extent in the literature is 
that the structural matrix and composition of the vehicle may undergo changes during 
application. Medications are typically applied to the skin as a thin layer under non-occlusive 
conditions and are intended to deliver the active ingredient for hours. After application, the 
composition of the formulation may change, commonly because of evaporation of volatile 
components (1). Such a change in the composition of a multi-component system likely elicits 
alterations of the phase structure of the system and of the concentration and distribution of the 
active ingredient in it. These alterations in turn can affect delivery performance. Consequently, 
the transformation of the formulation while on the skin surface may be a crucial factor 
determining drug delivery. 
This influence of loss of volatile components on drug permeation was studied mostly with 
volatile solutions or was not always related to its effect on drug permeation. An early work 
highlights the importance of the rising drug concentration due to loss of volatile components as 
a possible mechanism to enhance percutaneous absorption of steroids, compared to occlusive 
application (9). Similar results were presented for minoxidil and water/ethanol/propylene glycol 
solutions as volatile vehicles (10). An interesting publication presents a drug delivery device 
where the evaporation of ethanol from an ethanol-water mixture increased the skin-vehicle 
partition coefficient, which compensates for the loss of drug due to skin permeation (11). The 
consequence is a near zero order flux over a long time-range and an absence of large excess 
of drug in the donor reservoir. Other investigations focus more detailed possible changes 
dermatological formulations undergo following application, but without correlating the 
observations with drug delivery (12,13). The common, but valuable conclusion of these studies 
is that the phase diagrams may reflect the arising structures during evaporation. The 
dependence of drug delivery on alterations multi-phase dermatological formulations undergo 
due to evaporation of volatile components, however, is restricted to a few systematic studies 
(14,15). 
The goal of the present work was to investigate the dependence of drug skin permeation on 
the microstructure of multi-phase dermatological o/w formulations and, importantly, on 
alterations these formulations undergo due to evaporation of volatile components following 
application. The studied o/w formulations consisted of phospholipids, triglycerides, emulsifier, 
ethanol and water in proportions covering a wide range of values. These formulations were 
designed specifically for investigating the effect of mass fraction of formulations and its change 
following application on transdermal delivery. Sodium nicotinate was used as model 
hydrophilic drug. For interpretation of permeation data, a model is proposed that considers 
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drug distribution among distinct phases of such dispersed systems and postulates that 
continuous phase drug concentration alone governs drug permeation kinetics. 
Coexisting structures of the different formulations were separated by ultracentrifugation and 
identified by freeze fracture scanning electron microscopy, chemical component analysis and 
particle size measurements. Methods were developed and optimized for determining the free 
drug concentration in the continuous phase of the formulations. Alterations the formulations 
undergo following application were examined with special emphasis on changing mass 
fractions of distinct phases in order to calculate the arising continuous phase drug 
concentration during application. Permeation experiments were carried out in-vitro using pig 
ear skin as a model for human skin (16). An optimized amount of formulation was applied in 
order to detect obvious alterations of the formulations and to theoretically determine steady 
state flux values that facilitate the data evaluation. This was deemed appropriate for reaching 
the specific goals of this study. 
 
2 Materials and methods 
2.1 Materials 
Nicotinic acid was purchased from Sigma (St. Louis, MO, USA). Mygliol 812N®, medium chain 
triglycerides, was a gift from Hüls AG (Witten, Germany). NAT 8539®, consisting of 25 weight-
% EtOH and 75 weight % Phospholipon 80, a soy bean lipid extract with 76 weight-% 
phosphatidylcholine, was a gift from Phospholipid GmbH (Cologne, Germany). Polysorbate 20, 
Sodium dihydrogenphosphate Dihydrate and Sodium azide were purchased from Fluka 
Chemie GmbH (Buchs, Switzerland). Alcohol dehydrogenase 100mg (3.4ml) suspension, 
Aldehyde dehydrogenase, lyophilized powder, 250U and NAD, free acid, grade II, approx.98%, 
were purchased from Roche Diagnostics AG (Rotkreuz, Swizterland). Tetra-n-butylammonium 
hydrogensulfate LiChropur, CombiTitrant5, a one-component reagent for the volumetric Karl 
Fischer titration, methanol and tetrahydrofurane, Lichrosolv, were obtained from Merck 
(Darmstadt, Germany). Acetonitril (HPLC, gradient grade) was obtained from Biosolv 
(Valheesward, Netherlands). 9-Anthryldiazomethane was purchased from Serva 
Electrophoresis, (Heidelberg, Germany). All other chemicals and reagents used in this study 
were of analytical grade. Bidistilled water was used in all cases. 
2.2 Preparation of formulations 
The representative formulations (Table 1) were prepared by mixing NAT 8539® and tocopherol 
with the ethanol (mixture 1), dissolving the nicotinic acid in phosphate buffer (β= 0.01) adjusted 
to pH of 7.4 (mixture 2) and suspending polysorbate 20 in Mygliol 812N® (mixture 3). For 
manufacturing CF10 and CF50, in a first step mixture 2 was added to mixture 3 and 
homogenised for 5 minutes at 20000 rpm using a Polytron Pt 3000 (Kinematica AG Littau, 
Switzerland). Subsequently, mixture 1 was added and the product was homogenised once 
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again for 5 minutes. E was produced by adding mixture 2, additionally containing the ethanol, 
to mixture 3, and LD was obtained by adding mixture 1 to mixture 2, followed by 
homogenisation as above. Xanthan gum was added at the end to the formulations followed by 
futher short homogenisation, except for the formulations that were used for ultracentrifugation. 
A purely aqueous gel with a drug load of 1 weight-% nicotinic acid was produced by adding 0.5 
weight-% xanthan gum to mixture 2. In all cases, the formulations were allowed to equilibrate 
for at least 24 hours before use. The pH was measured with a pH-meter 691 and a sensor type 
Porotrode (Metrohm AG, Herisau, Switzerland). A pH value in the range of 7-7.5 was required 
to receive deprotonation of the nicotinic acid to nicotinate. 
2.3 Chemical component analysis of the formulations 
Chemical component analysis of the received fractions following ultracentrifugation (see 2.4) 
was performed as follows: Phospholipids were quantified by determination of anorganic 
phosphate after digestion of the phospholpids with a sulphuric/perchloric acid mixture. A 
spectroscopic method based on the formation of a coloured complex of phosphomolybdate 
with malachite green absorbing at 610 nm was applied (17).  
Water was assayed by Karl-Fischer titration using a KF 701 Titrino (Metrohm AG, Herisau, 
Switzerland) and a one-component reagent CombiTitrant 5. The titer was exactly determined 
with double distilled water prior to every analytical run.  
EtOH was quantified by an enzymatic method (18), based upon spectroscopic determination of 
accumulated NADH at 340 nm using a Perkin Elmer Spectrometer Lambda 20 (Perkin Elmer, 
Ueberlingen, Germany).  
Sodium nicotinate, expressed as nicotinic acid, was assayed by HPLC (Hewlett Packard, 
series 1050, Hewlett Packard, Waldborn, Germany). A reversed phase RP-18 column (CC 
125/2 Lichrospher 100-5 RP-18 ec) was used. The mobile phase consisted of phosphate 
buffer (pH 7.4, β=0.05), containing 5mM tetrabutylammonium hydrogenphosphate and 5% 
methanol. The flow rate was 0.25 ml/min. Detection was performed UV-spectrophotometrically 
at 214 nm. Sodium nicotinate extraction from the samples was done after suitable dilution with 
buffer pH 7.4 by sonification for 5 minutes. The samples were filtered through a siring filter 
(Titan 2, PTFE, 0.2 µm, Sun Sri, NC, USA) prior to injection. 
Continuous phase nicotinate concentration was quantified following ultrafiltration using 
centrifugal filter devices (Microcon YM3) with a molecular weight cut-off of 3000 (Millipore, 
Bedford, MA, USA).  
Triglycerides and polysorbate 20 were quantified by HPLC following saponification and 
derivatisation of the fatty acids with 9-anthryldiazomethane (ADAM) (19). Briefly, samples were 
weighted into eppendorf tubes and treated with 0.5 ml 1N NaOH solution (80% ethanol/ 20% 
water) during 7 hours at 60°C. After acidification with 0.2 ml 5N HCl, the free acids were 
extracted with 0.6 ml methylene chloride. 0.01 ml of this extract was added to 0.29 ml of 
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methanolic ADAM-solution (0.15%) and allowed to react for at least 1 hour at 25°C, protected 
from light using brown glass HPLC vials. The same chromatographic equipment as for the 
nicotinic acid assay was used. The injection volume was 10 µl and the composition of the 
mobile phase, flow rate 0.3 ml/min, was varied in a gradient mode as follows: mobile phase A 
consisted of 85 % acetonitrile and 15% water and mobile phase B contained 10 % THF and 
90% acetonitrile. 0 -18 min: 100% A, 18- 30 min linear change to 100% B, 30-40 min 100% B, 
40-50 min 100% A. The ADAM esters were detected at 255 nm.  
2.4 Physical methods to characterise the formulations 
Formulations were fractionated by ultracentrifugation using an ultracentrifuge type Centricon T-
1075 and a rotor TFT 7013 (Kontron Instruments, Mailand, Italy), and Quick-Seal centrifuge 
tubes, 5/8X3 (Beckman Instruments, Palo Alto, USA). Formulations CF10 and LD were 
centrifuged for 2 hours, and CF50 and E for 1 hour at 222000-450000 g, xanthan gum omitted. 
The different operation times were optimised to fractionate intact structures. 
Sample preparation for cryo-raster electron microscopy was done as follows: small droplets of 
the formulations were mounted on a specimen table and rapidly frozen in liquid propane at -
196°C. Further processing and observation was perfo rmed in a Balzer SCU 020 cryo-
preparation unit attached to a Joel JSM 6300 scanning electron microscope. The frozen 
samples were fractured in a high vacuum of less than 5*10-6 bar and a temperature of –100°C, 
followed by sputtering with gold (layer thickness 10nm) and observed with an acceleration 
voltage of 10 kV. 
The z-average of liposomal vesicles was determined by photon correlation spectroscopy using 
a Malvern Zetasizer 1000HSa (Malvern Instruments Ltd., Malvern, UK). All measurements 
were carried out at 25°C. Samples were diluted with  filtered buffer pH 7.4 until counting rates 
between 100 and 300 KCts/s were reached. The mean diameter of emulsion droplets was 
determined by laser diffraction using a Mastersizer S (Malvern Instruments Ltd., Malvern, UK) 
with a small sample unit and a beam lens with 300 mm focal distance. All samples were diluted 
till an obscuration of approx. 20% was reached. 
2.5 Permeation experiments 
Skin permeation was studied in Franz-type diffusion cells at 32°C with a surface diffusion area 
of 1.7-1.8 cm2 across excised full thickness pig ear skin. The ears of domestic pigs were 
obtained from a local abattoir no more than a few hours post-mortem. The skin was separated 
from the cartilage tissue by a scalpel, stored in a freezer at –75°C and was used within 4 
weeks. The receiver medium for the permeation experiments with a volume of 8.5 to 9 ml 
consisted of an aqueous phosphate buffer solution, pH 7.4, β=0.05, additionally containing 
0.1% of sodium azide as a preservative. Skin integrity was tested by transepidermal water loss 
(TEWL) measurements (Tewameter TM 210, Courage Khazaka electronic GmbH, Germany) 
after 4 hours of equilibration prior to the application of the formulations. Then, a practically 
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infinite dose of formulation of 570 mg/cm2 was applied non-occlusively to the donor 
compartment. At predetermined time intervals, samples of the receiver medium were collected 
and replaced by fresh buffer. The entire duration of an experiment was 54.5 hours. The 
samples were analysed directly for sodium nicotinate concentration by HPLC (for conditions 
see section 2.3.) without further treatment except centrifugation for 5 min. at 15800 g. 
Permeation from a purely aqueous gel was studied equally, but under occlusive conditions to 
keep the donor concentration constant. 
2.6. Evaporation studies 
Formulations were allowed to evaporate on the skin surface, conditions according to the 
permeation experiments (see 2.5). At representative time points, the formulations were 
removed from the skin surface, analysed for remaining water and ethanol (see 2.3) and 
microscopically inspected between crossed polarizers using a Zeiss light microscope (Zeiss, 
Oberkochen, Germany). 
In addition, 150g-batches of the formulations were produced without xanthan gum and allowed 
to evaporate in a glass container situated in a water bath of 32° C without stirring. The amount 
of remaining ethanol and water was determined frequently (for conditions see 2.3). 
Corresponding electric conductivity was measured with a Conductometer 660 and a 
conductivity-measuring cell 60323110, cell constant 0.8 cm-1, (Metrohm AG, Herisau, 
Switzerland) at 32 °C. CF10 was additionally evalua ted by ultracentrifugation and chemical 
component analysis after evaporation to an amount of remaining water that corresponded to 
the situation at the end of the permeation experiments. 
2.7 Maximum solubility determination 
For solubility determination, sodium nicotinate was prepared first from nicotinic acid. For this 
purpose, the commercially available nicotinic acid was dissolved and adjusted to a pH of 
around 7.5, followed by evaporation of the water under vacuum using a Rotavapor (Büchi, 
Fluwil, Switzerland) at 40°C. The received sodium n icotinate was dried and stored over silica 
gel in a desiccator.  
In order to estimate saturation concentrations in a solution or preparation, the dry sodium 
nicotinate was added until precipitation occurred. This mixture was stirred for 8 hours at 32°C, 
14 hours at 4°C and again 8 hours at 32°C. Subseque ntly, the supernatant received after 
centrifugation for 30 min. (15800g) was analysed for sodium nicotinate (for conditions, see 
2.3). 
3 Results and discussion 
3.1 Characterisation of the original formulations 
The aim of the present work was to investigate the dependence of drug delivery on possible 
alterations representative dermatological formulations may undergo after application. For that 
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purpose, the microstructure of these formulations (Table 1) was of primary interest. First, 
scanning electron microscopy (SEM) was used to visualize the dispersed structures. Fig.1 a,b 
demonstrates the dissimilar appearance of micrographs obtained from emulsion droplets and 
liposomes, which are the typical structures of formulations E and LD, respectively, conditioned 
by their composition. Hence, these micrographs were used to relate the images of formulations 
CF10 and CF50, which are of more complex composition (Table 1), to one or both of these 
structures. In case of CF10, a discrimination between two different structures with similar 
appearance to the liposomes of LD and to the emulsion droplets of E is obvious, while the 
image of CF50 showed only one population of dispersed structures which appeared more 
similar to emulsion droplets than to liposomes (see Fig.2 a,b). The visible diameter of these 
structures, however, was clearly larger for CF10 than for CF50 and E, while the structures that 
appeared more similar to the liposomes of LD were smaller in size within CF10, almost near 
the resolution limit of the scanning electron microscope.  
Laser diffraction was used to measure the mean diameter of the larger structures, related to 
emulsion droplets, for CF10, CF50 and E (Table 2). These measured droplet diameters agreed 
well with the estimated diameters considering the micrographs of CF50, CF10 and E. Laser 
diffraction, however, is not suitable to detect smaller dispersed structures, for example 
liposomes, beside larger dispersed structures, for example emulsion droplets.  
For that reason and to further characterise the microstructure of formulations, comprising 
structures were separated using ultracentrifugation. LD and E yielded the following fractions 
(Fig.3): The emulsion E a turbid, white fraction on top (fraction A) and a clear colorless fraction 
(fraction B) in the bottom and the liposomal dispersion LD a clear colorless fraction on top 
(fraction B) and a turbid, yellow-brown, which is also the colour of the bulk-phospholpids NAT 
8539, fraction (fraction C) in the bottom. The outcome of this examination was that liposomes 
and emulsion droplets may be identified due to their behaviour following ultracentrifugation in 
case of the investigated formulations. CF10 gave three fractions with similar appearance to the 
described fractions A, B and C, strongly supporting the conclusions drawn from the SEM-
images of coexisting emulsion droplets and liposomes (Fig.3). The clear fraction B of CF10, 
however, was little yellowish compared to this fraction of LD and E, indicating the presence of 
phospholipids, either due to incomplete fractionation of small liposomes or due to the presence 
of other structures that comprise phospholipids. Furthermore, the fractionation of the structures 
allowed analysing fraction C of CF10, which was supposed to contain liposomes, and this 
fraction of LD for particle sizes of comprising structures by photon correlation spectroscopy 
(PCS). These measurements could verify the observations based upon the electron 
micrographs above of smaller structures that appeared similar to liposomes within CF10, 
compared to the liposomes within LD (Table 3). All these observations were additionally 
confirmed considering the micrographs of the isolated fractions A and C of CF10 (Fig.4 a,b). 
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The image of fraction C showed only structures which appeared similar to the structures of LD, 
while fraction A revealed only the structures that were related to emulsion droplets, considering 
the SEM-image of E. 
In case of the complex formulation with 50% dispersed phase (CF50), an isotropic clear, but 
strongly yellowish fraction in the bottom and a fraction in the top of similar appearance to the 
fractions A of CF10 and E appeared following ultracentrifugation, but no turbid brown fraction 
in the bottom (Fig.3). This supported the assumed presence of emulsion droplets and the lack 
of liposomes within this formulation, according to the interpretation of the electron microscopic 
inspection. Electron microscopy of the clear yellow fraction of CF50 gave an image without 
recognisable structure, likewise the clear fractions of the other formulations, while the 
micrograph obtained from the turbid white fraction A of CF50 showed closed packed, intact oil 
droplets (micrographs not shown). This is a good support for the validity of ultracentrifugation 
to separate intact structures of o/w dermatological formulations, which was also indicated by 
equal measured particle sizes for dispersed structures of the complete formulations as for the 
separated fractions containing these structures (Table 2, Table 3). 
In a next step, we estimated the distribution of the formulation compounds between the 
separated structures of the formulations following ultracentrifugation by chemical component 
analysis of the received fractions (Table 4). Triglycerides were present in large amounts in 
fractions A of CF10, CF50 and E, and phospholipids in fractions C of CF10 and LD, supporting 
the conclusions drawn above that liposomes were sedimenting and emulsion droplets were 
creaming in case of the investigated formulations. For CF50, where no liposomal structures 
were formed, phospholipids were found mainly in the clear, yellow fraction, accompanied by 
remarkable amounts of polysorbate 20 and triglycerides (Table 4). Interestingly, the sum of 
these compounds within this fraction amounted about 35 weight-%. For comparison, the 
formulations CF10 and LD, which were both of turbid, milky appearance, included around three 
times less of triglycerides, polysorbate 20 and/or phospholipids. In addition, rheological 
inspections of the separated clear, yellow fraction of CF50 showed Newtonian flow behaviour 
(data not shown), strongly indicating the presence of a microemulsion within this formulation 
beside the emulsion droplets.  
Per definition, a microemulsion consists of aqueous phase, organic phase and a 
surfactant/cosurfactant component, arises spontaneously, is thermodynamically stable and 
shows Newtonian flow behaviour (7,20). All these attributes are valid for the discussed 
structure. Interestingly, fraction B of CF10 also contained small amounts of triglycerides, 
phospholipids and polysorbate 20 in a roughly comparable ratio to the clear fraction of CF50, 
while the clear fractions of LD and E contained negligible amounts of phospholipids and 
triglycerides, respectively. This finding may explain the slightly yellowish colour for fraction B of 
CF10 mentioned above and indicated here again the formation of a spontaneously arising 
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system, rather than an incomplete fractionation of the liposomes and emulsion droplets 
following ultracentrifugation. As consequence, it is postulated that microemulsion structures 
consisting of phospholipids, triglycerides, polysorbate 20, aqueous buffer and ethanol may 
arise spontaneously if all these components are present. This implication is supported by the 
lack of liposomes within formulation CF50, where enough polysorbate 20 and triglycerides 
were present to incorporate all phospholipids in the microemulsion structure, while the 
relatively low polysorbate 20 content of CF10 very likely facilitated the formation of liposomal 
structures. 
Furthermore, the chemical component analysis showed that the fraction C of CF10, identified 
as liposomes above, contained, in addition to predominantly phospholipids, considerable 
amounts of triglycerides and polysorbate 20 (Table 4). This is a possible explanation for the 
reduced vesicle size compared to the formulation LD (Table 3). The smaller z-average is 
considered due to a steric repulsion among the incorporated surfactant, which may increase 
the liposome particle curvature, and finally decreases the vesicle diameter (21).  
Hence, all these results point out that the arising structures of multi-component dermatological 
formulations cannot be easily related to typical structures that are formed by single use of the 
compounds. Furthermore, the presence of phosholipids includes not automatically the 
formation of liposomes, an observation also reported by other working groups (22,23). To 
summarize, our representative dermatological formulations included a wide variety of possible 
structures, such as: conventional emulsion droplets, liposomes and microemulsion structures.  
To test a possible dependency of transdermal drug permeation on these microstructures, we 
postulated that continuous phase drug concentration of a multi-phase formulation is the only 
parameter governing permeation kinetics (see 3.3). Determination of this concentration, in turn, 
includes the exact information about the composition of the continuous phase and about drug 
distribution between this phase and dispersed structures. A constant ratio of water to ethanol 
for every received fraction following ultracentrifugation and for the ratio of these components of 
the corresponding complete formulation in case of all formulations strongly indicated that the 
sum of water and ethanol amount to the continuous hydrophilic phase, independently of 
dispersed structures of the studied o/w formulations. This is demonstrated in Fig.5. To test the 
distribution of the sodium nicotinate among distinct phases, the same analysis was performed 
by plotting the total amount of hydrophilic phase of a specific fraction following 
ultracentrifugation against the corresponding amount of the model drug. This demonstrated in 
the same way as for the ethanol a complete distribution of the sodium nicotinate into the 
continuous hydrophilic phase for all formulations (Fig.6). Ultrafiltration experiments confirmed 
this finding and provide a faster and easier methodology to determine continuous phase drug 
concentrations of hydrophilic drugs for o/w formulations (Table 5).  
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3.2. Alterations of the formulations due to evaporation 
Dermatological vehicles are typically applied non-occlusively and, thus, may undergo 
considerable compositional changes due to evaporation of volatile components. Therefore, 
alterations of the study formulations during and after evaporation of water and ethanol, which 
were the volatile components, were investigated. The cumulated amount of these compounds 
remaining in the formulations as a function of time, conditions according to the permeation 
experiments (see 3.3), is shown in Fig.7. CF10 and LD, both comprising an equal, relatively 
large volatile continuous phase before evaporation, showed comparable evaporation pattern. 
In case of CF50 and E, which initially contained a comparatively small amount of volatile 
phase, CF50 retained more water than E. It is worth mentioning that ethanol evaporated faster 
than water and was undetectable 30 hours after application, independently of the formulation 
structure. 
To investigate alterations due to loss of volatile components of the formulations more detailed, 
practically big amounts were allowed to evaporate to final water contents that corresponded to 
the end of the permeation experiments. First, CF10 was allowed to evaporate to remaining 
water content of about 50%, precisely determined by Karl-Fischer titration. This formulation 
gave by ultracentrifugation three fractions, as observed before evaporation, but with a turbid 
brown fraction of equal appearance to the liposomal fraction (fraction C) of the original CF10 in 
the middle of the centrifugal tube, and a clear, yellow fraction (fraction B) in the bottom. This 
observation indicated a switch in the order of fractions C and B as well as potential 
compositional changes of fraction B because of the deepened yellow colour. 
On basis of the remaining water of this complete formulation after evaporation, the amount of 
non-volatile components was calculated with the objective to prepare a formulation with similar 
composition. This simulated formulation gave also three fractions following ultracentrifugation 
that appeared comparable to the fractions received from CF10 after evaporation. Hence, all 
the received fractions of both formulations were analysed for their chemical composition as 
established for the initial formulations (Table 6). Interestingly, the fractions of the simulated 
formulation had a comparable chemical composition to the fractions received after evaporation 
of CF10. As consequence, the conclusion may be drawn that the arising phase structures 
during evaporation are predictable on the basis of composition alone, supporting the work of 
other groups (12,13).  
Interpretation of the chemical composition of the individual fractions given in Table 6 more 
detailed supported the assumption of the switch in the order of the initial fractions B and C 
above. After evaporation, the brown fraction, although still comprising quantities of 
phospholipids, included also remarkable triglycerides and polysorbate 20, and triglycerides are 
of lower density, compared to phospholipids. The clear fraction, in turn, was enriched with 
phospholipids, triglycerides and polysorbate 20, compared to fraction B of the original CF10, 
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which also comprised a small quantity of microemulsion aggregates (Table 4). Furthermore, 
comparing the ratios of these components of the fractions B and C before and after 
evaporation (Table 4; Table 6) demonstrates that the ratio from phospholipids to triglycerides 
and polysorbate 20 increased for fraction B, while the ratio of phospholipids to these 
compounds decreased for fraction C after evaporation. Hence, a solubilisation of the vesicles 
is postulated as a preliminary state before a transition of the phospholipids from vesicle to 
microemulsion took place. The fact that the investigated formulation CF10 after evaporation, 
which is analogues to the original CF50 when buffer changes the ethanol, comprised 
liposomes, but not CF50, was supposed to be due to the presence of the ethanol in case of the 
latter. 
The difference in chemical composition of fraction A of the formulation after evaporation, 
compared to this fraction of the prepared formulation with equal composition, was very likely 
due to an observed coalescence of the emulsion droplets during evaporation. It should be 
mentioned that the data given in Table 6 are no averages of several experiments because it 
was impossible to fix the exactly same remaining amount of water of a formulation after 
evaporation, but the examination was repeated with a formulation that was allowed to 
evaporate to comparable amount of remaining water, which gave the same results (data not 
shown). 
In case of CF50, ultracentrifugation was impossible after evaporation of volatile components 
because of the big amount of dispersed phase. However, for this formulation, a phase 
inversion from o/w to w/o was detected by conductivity measurements during evaporation 
when the remaining water content fell below a value of about 20 weight-%, while the same 
inspection of formulation E, initially containing an equal phase ratio of dispersed to continuous 
phase, gave no phase inversion (Table 7). This may also explain the larger amount of retained 
water for CF50 after evaporation, compared to E (see above). Hence, multi-phase formulations 
that contain polysorbate 20, triglycerides and phospholipids seem to be able to form w/o 
systems during evaporation of volatile components, but not the more simple emulsion. 
Possibly the amphiphilic nature of the phospholipids is responsible for the formation of w/o 
systems (22). In order to verify this assumption, a big amount of CF10 was also allowed to 
evaporate to a remaining water content in the same order of magnitude to CF50 after 
evaporation, which also yielded a w/o formulation (Table 7). 
In case of formulation E, ultracentrifugation was also not possible after evaporation for the 
same reason as described above for CF50. However, microscopic inspection using crossed 
polarizers revealed the formation of acicular crystals during evaporation of this formulation 
when the remaining water content fell below a value of about 18 weigh-% (Fig.8). A buffer 
solution that contained sodium nicotinate generated the same crystals after evaporation, but 
not a drug-free formulation. The sodium nicotinate precipitation within E was found to be due to 
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a decrease of its maximum solubility in the remaining buffer after evaporation. After 
coalescence of the emulsion droplets, that was the macroscopically and microscopically 
observed situation after evaporation, the polysorbate 20 was supposed to distribute into the 
remaining aqueous buffer due to its hydrophilicity (HLB 17). This polysorbate 20/buffer mixture 
was simulated to determine the maximum sodium nicotinate solubility in it. This maximum 
solubility was 41.27 mg/g, while the maximum solubility in a purely aqueous buffer was about 
one order of magnitude larger and gave a value of 445.69 mg/g. This result will be crucial for 
the interpretation for the permeation experiments (see 3.3), but the reason for this effect and 
why no drug precipitation took place during evaporation of the other formulations was not 
further investigated. 
3.3 Permeation studies 
The dependence of the discussed microstrutures and alterations due to evaporation of volatile 
components following non-occlusive application on sodium nicotinate skin permeation was 
studied. Permeation from an occlusively applied purely aqueous gel was determined as 
reference. Fig.9 shows that the cumulative drug permeation differed between the four 
formulations and was for all of them higher, compared to the gel. This effect was observed 
previously for volatile solutions and explained by the increasing concentrations of drug during 
evaporation (9,10). However, closer examination of the experiments obviously demonstrated 
that CF10 and LD exhibited continuously increasing drug fluxes during the investigated time, 
while the formulations E and CF50 showed linear and decreasing permeation profiles, 
respectively. This could not be easily related to overall rising drug concentrations, and was 
also not due to deterioration of skin barrier function, as attested by the reference gel 
formulation that gave linear sodium nicotinate permeation with time. Hence, a model was 
developed to interpret the permeation data that considers the situation within the formulations, 
i.e. the partition of the drug and the phase ratio of dispersed to continuous phase of multi-
phase formulations. In order to quantify the results, it is postulated that only the drug 
concentration in the continuous phase governs permeation kinetics. The drug concentration 
within distinct phases of a multi-phase formulation is given by:  
 
dispdispcontconttot CCC ⋅+⋅= φφ    (1) 
 
where, Ctot is the overall drug concentration in the formulation, Ccont and Cdisp the concentration 
of the continuous and dispersed phase, respectively, and φcont and φdisp the mass-fraction of the 
continuous and dispersed phase, respectively. These mass fractions are given by: 
 
tot
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where, Mtot, Mcont and Mdisp, denote the mass of the total formulation, of the continuous phase 
and of the dispersed phase, respectively. The distribution of a drug between the dispersed and 
the continuous phase can be expressed as the partition coefficent Kd/c: 
 
cont
disp
cd C
C
K =/      (3) 
 
A combination of Eqs. (1), (2) and (3) offers the term to calculate continuous phase drug 
concentration: 
 
1)1()1( / +−⋅−
=
cdcont
tot
cont K
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Eqs. (1), (2) and (4) are of general validity. Thus, some additional considerations are 
necessary to apply them to the situation of non-occlusive application. The fractions φcont and 
φdisp may change, which, in turn, affects the concentrations Ctot, Ccont and Cdisp. Furthermore, a 
change of the composition of the fractions may also influence the partition coefficent Kd/c. 
Hence, the superscript t is introduced to denote the arising conditions during evaporation, and 
the superscript 0 will symbolize the situation in the according original formulation for further 
discussion.  
For o/w formulations, it is assumed: (I) evaporation of the continuous phase with time, (II) no 
evaporation and negligible skin permeation of the dispersed phase and (III) no drug 
precipitation and negligible drug permeation. Then, during evaporation, the following 
correlations may be set up: 
t
tot
tot
tot
t
tot
C
C
M
M 0
0 =      (5) 
 
)1(
)1( 0
0 t
cont
cont
tot
t
tot
M
M
φ
φ
−
−
=     (6) 
 
Finally, the combination of Eqs. (4), (5) and (6) offers a general term that allows calculating 
continuous phase drug concentration at a specific state during evaporation of a multi-phase 
formulation:  
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Because of the observed drug precipitation within formulation E and the phase inversion that 
took place in case of CF50 during evaporation, the model was applied to the permeation data 
of formulations CF10 and LD. For this purpose, the partition coefficient Kd/c for sodium 
nicotinate was assumed as zero. Thus, the overall drug concentration at a specific state during 
evaporation may be calculated as: 
 
t
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Furthermore, Eq. (7) may be simplified and gives the term:  
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However, more than 10 weight-% of the applied sodium nicotinate was removed from the 
formulations due to skin permeation during the experiments. Thus, it was deemed appropriate 
to correct the overall concentrations. These concentrations are given by: 
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where, mNA,0 and mNA,Rt denote the applied mass of sodium nicotinate, expressed as nicotinic 
acid, in the complete formulation at time zero and the mass transported to the receiver at time 
t, respectively. Finally, the combination of Eqs. (6), (9), (10) and (11) offers a term to calculate 
continuous phase drug concentration for CF10 and LD for the situation during evaporation of 
volatile formulation compounds considering the conditions of the permeation experiments of 
this work: 
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The validity of this term was demonstrated by measuring continuous phase sodium nicotinate 
concentrations of LD and CF10 using ultrafiltration. The chosen remaining water contents for 
that examination corresponded to the end of the permeation experiments and were the basis 
for the value of the specific φtcont in the calculation. These concentrations were in very good 
agreement with the calculated values with Eq. (12) (Table 8). 
In order to calculate continuous phase drug concentrations for the analysis of permeation data, 
the term φtcont is approachable from the evaporation profile if permeation and evaporation were 
investigated under the same experimental conditions. Finally, on basis of the overall drug 
concentrations and continuous phase drug concentrations, two different permeability 
coefficients may be calculated to interpret the permeation data: 
 
t
tot
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where, Papp is the apparent permeability coefficient, calculated with the overall drug 
concentration at a specific state during evaporation, and Pint is the intrinsic permeability 
coefficient at that time, calculated with continuous phase drug concentration. Jt+D denotes the 
sodium nicotinate flux that was related to these concentrations, respectively. This flux, 
however, may be the result of a donor concentration some time before the current time that 
was used to determine Jt+D. Thus, this assumed time delay, symbolised with the subscript +D, 
was estimated. For that purpose, several experiments were performed by changing an 
aqueous gel containing 1.1 weight-% of sodium nicotinate, expressed as nicotinic acid, after a 
fixed time point with a quadruple more concentrated gel. Fig. 10 shows that this time is just 
about 2 hours, while the conventional lag time till steady state flux was reached, calculated 
from the same permeation profile, was much longer. As consequence, a delay of two hours 
between the calculated concentrations of the formulations and the resulting drug fluxes Jt+D 
was considered for the calculation of the permeability coefficients according to Eqs. (13) and 
(14). Because of the steadily increasing drug fluxes in case of CF10 and LD during the 
permeation experiments (see above), different drug fluxes were calculated, each with the slope 
of two consecutive data points obtained from the permeation pattern in-between 2670 and 
3270 minutes (Fig.9). This entire time was also used to estimate the corresponding φtcont from 
the evaporation profile, assuming linear kinetics for the evaporation during this time slice 
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(Fig.7). Finally, all possible Papp and Pint values for CF10 and LD were calculated using Eqs. 
(8), (12), (13) and (14). 
To test the hypothesis that continuous phase drug concentration governs transport kinetics, 
these Papp and Pint values were plotted against the corresponding small time intervals that were 
used to calculate the fluxes Jt+D (Fig.11, Fig.12). The diagrams demonstrate that the Papp 
values tend to increase with time, which may be attributed to weaker rising overall drug 
concentrations of the formulations during evaporation, compared to continuous phase drug 
concentrations. If this assumption exclusively explains the observation of rising Papp values 
with time, the permeability coefficient calculated with continuous phase drug concentrations, 
referred to as Pint, should be constant with time. This tendency was observed (Fig.11, Fig.12) 
and demonstrated that continuous phase drug concentration explains the transport kinetics 
more precisely than the overall drug concentration and supports strongly our hypothesis above 
that this concentration is responsible for the arising drug flux during evaporation. Hence, all the 
intrinsic permeability coefficients of CF10 and LD, which were calculated as described, were 
averaged in order to obtain one permeability coefficient for further discussion for these 
formulations. 
For formulation E, the precipitation of sodium nicotinate was assumed to be the reason for the 
obtained constant drug flux during the analysed time between 2670 and 3270 min. 
Consequently, intrinsic permeability coefficients were obtained by Eq. (14) from the slope of 
the permeation pattern within this entire time and the saturation concentration of the drug in 
the aqueous polysorbate 20/buffer solution that resulted after evaporation of volatile 
components (see 3.2). Permeation data obtained form the purely aqueous gel were analysed 
equally using the theorectical concentration as Ctcont for the calculation with Eq. (14).  
Table 9 finally gives the averaged intrinsic permeability coefficients from several repeated 
experiments for all formulations, calculated with continuous phase drug concentration. The 
data of CF10 and LD are the mean of averaged intrinsic permeability coefficients over the 
entire analysed time as discussed above. It is obvious that all these formulations gave strongly 
similar intrinsic permeability coefficients, while the cumulative permeated drug amount varied 
about tenfold for CF10 and LD, compared to the gel, and about twofold compared to E (Fig.9). 
This clearly demonstrates that the obviously varying permeability from the employed 
formulations may be explained by continuous phase drug concentration alone, without the 
need to consider formulation effects on skin barrier function. The data obtained from CF50 
were not included in the quantitative evaluation because of the phase inversion that took place 
under the experimental conditions. Nevertheless, that result also points out a possible event 
due to evaporation of volatile components after application of a dermatological formulation 
and, hence, how this effect may affect drug permeation. 
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Dermatological medications are typically applied as a thin layer and will remain on the skin 
only for a few hours, which are not exactly the conditions for the studies described in this work. 
Hence, the discussed alterations of formulations due to evaporation of volatile components 
likely take place much faster in clinical situations. Furthermore, the residue of formulation may 
be removed before steady state drug flux is reached, commonly due to mechanical agitation. 
The applied experimental conditions, however, were deemed appropriate for reaching the 
specific goals of this study and allowed observing alterations following formulation application 
in `slow-motion`. Although enhancer properties for microemulsions (4) and liposomes (24) or a 
drug-carrier function for the latter (25,26) were not confirmed, the proposed concept provides a 
tool for studying and predicting skin permeation in the situation of non-occlusive application. It 
further demonstrated that continuous phase drug concentration, if not considered, may 
superimpose a dissolution dependency in the delivery rate. Furthermore, the concept also 
provides a methodology to identify possible enhancer properties of appropriate formulations, 
which is the aim of a current project in this lab and will be reported in the future.  
 
4.Conclusion 
In conclusion, the microstructure of representative multi-phase dermatological formulations, 
different phase transitions these formulations may undergo due to evaporation of volatile 
components and how these parameters affect drug delivery was pointed out. Dermatological 
o/w formulations consisting of triglycerides, phospholipids, emulsifier and hydrophilic phase 
have the potential to form emulsion droplets, vesicles and microemulsions, conditioned by their 
individual composition. Depending on compositional changes during evaporation of volatile 
components, phase transitions including conversion of vesicle to microemulsion, drug 
crystallisation and o/w to w/o inversion took place in the employed formulations. These results 
are based upon a combination of different characterisation methods for multi-phase 
dermatological formulations, comprising a new methodology that includes chemical component 
analysis of separated microstructures following ultracentrifugation.  
Dependence of drug skin permeation on the kind of non-occlusively applied vehicles and on 
the alteration vehicles undergo due to evaporation can be quantitatively described by a 
proposed model taking into consideration continuous phase drug concentration, independently 
of the existing dispersed structures. This model offers a predictive tool to correlate the arising 
continuous phase drug concentration of a formulation during evaporation of volatile 
components with drug permeation from this formulation and, possibly, to delineate the 
regulation of skin permeation by the formulation as a result of controlling continuous phase 
drug concentration or as a result of affecting skin barrier function.  
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b. 
Figure 1 SEM-Images; formulation E (a.), formulation LD (b.) 
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a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. 
Figure 2. SEM-Images; formulation CF10 (a.), formulation CF50 (b.) 
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Figure 3 Tubes with received fractions following ultracentrifugation of the individual 
formulations. A, B and C denote distinct fractions 
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a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. 
Figure 4 SEM-images of fraction A (a.) and C (b.) of CF10 received from ultracentrifugation of 
formulation CF10 
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Figure 5 Correlation between ethanol and water content of the fractions received from 
ultracentrifugation of the individual formulations. The plot also includes data of unfractionated 
formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Correlation between complete continuous phase (sum of water and ethanol) and 
sodium nicotinate content, expressed as nicotinic acid, of the fractions received from 
ultracentrifugation of the individual formulations. The plot also includes data of the 
unfractionated formulations 
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Figure 7 Evaporation pattern of the formulations, error bars denote standard deviations (time 
60/240/1230/1770 min. n=3; 3270 min. n=8; 2670 min. n=7 in case of the liposomal dispersion 
and formulation 1, the others n=3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Polarising microscopy of precipitated sodium nicotinate after evaporation of 
formulation E  
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Figure 9 Cumulative sodium nicotinate permeation, expressed as nicotinic acid, as a function 
of time, n=8. For simplicity, error bars are not shown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Effect of donor concentration and delay till the effect is detectable in the receiver 
compartement. After 2685 min., a donor solution containing 1.1% sodium nicotinate was 
replaced by solution that contained 4% of sodium nicotinate, expressed as nicotinic acid, 
respectively. 
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Figure 11 Plot of apparent and intrinsic permeability coefficients Papp and Pint, respectively, of 
formulation CF10 against the time points that were used to calulate the according fluxes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Plot of apparent and intrinsic permeability coefficients Papp and Pint, respectively, of 
formulation LD against the time points that were used to calulate the according fluxes  
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Tables 
 
Table 1 Composition of the formulations (in weight-%) 
 CF 10 a CF 50b Ec LDd 
Nicotinic acid 1.0 1.0 1.0 1.0 
Aqueous Buffer pH 7.4 73.85 34.9 36.92 74.25 
Ethanol 96% 14.1 6.6 9.98 11.82 
Mygliol 812N 6.75 36.0 47.9  
Polysorbate 20 1.35 8 4.0  
NAT 8539 2.4 13.38  12.33 
Tocopherol 0.05 0.1  0.1 
Xanthan gum 0.5 0.20 0.20 0.5 
aComplex formulation with 10 weight-% dispersed phase, bComplex formulation with 50 
weight-% dispersed phase, cEmulsion with 50 weight-% dispersed phase, dLiposomal 
dispersion with 10 weight-% dispersed phase 
 
 
Table 2 Mean diameter of emulsion droplets 
 CF10 CF50 E 
Complete formulation 2.87±0.25 1.48±0.125 1.44±0.078 
Fraction A 3.05±0.63 1.45±0.12 1.43±0.10 
The complete formulations and fractions A obtained from ultracentrifugation were analysed. 
Values result from laser diffraction measurements and denote µm ± SD, n=3 
 
 
 
Table 3 Z-average of liposomal vesicles 
 CF10a LD 
Complete 
Formulation 
 326±11 
Fraction C 169±11 325± 2.40 
The complete formulation and the fractions C obtained from ultracentrifugation were analysed. 
Values result from PCS measurements and denote nm ± SD, n=3. a The presence of emulsion 
droplets prohibited an determination of liposomes within the complete formulation 
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Table 4 Composition of received fractions following ultracentrifugation of all formulations 
 Nicotinic 
acida 
Watera EtOHa Phospholipisb Mygliol 812Nc Polysorbate 
20c 
Summation 
CF10        
A 0.95±0.04 66.50±2.17 11.23±0.87 0.74±0.13 12.54±6.02 1.49±0.64 93.43 
B 1.12±0.03 82.06±0.89 13.32±0.98 1.00±0.17 1.43±0.72 1.50±0.77 100.43 
C 0.83±0.06 59.24±3.17 9.77±0.51 15.64±5.04 2.98±1.88 5.03±0.84 93.49 
CF50        
A 0.83±0.06 12.17±1.90 3.53±1.18 5.61±1.85 74.11±3.62 3.89±1.70 99.66 
B 1.45±0.07 49.39±1.21 12.92±2.53 12.71±0.87 13.40±0.87 9.37±1.70 99.22 
LD 
       
A 1.19±0.03 83.90±0.60 14.37±0.14 0.14±0.17   99.60 
C 0.81±0.17 56.13±5.53 10.76±1.61 27.25±11.87   94.95 
E        
A 0.19±0.11 8.76±7.59 2.68±0.90  77.26±21.47 2.65±0.68 91.54 
B 2.08±0.03 74.96±1.97 15.75±0.71  0.22±0.14 5.33±0.37 98.34 
Values denote weight-% of each analysed component within a fraction A, B or C ± SD. an=4,b 
n=6-8, c n=3, Tocopherol was not determined. Summation is the sum of all determined means 
of all components for each fraction 
 
 
 
Table 5 Calculated and measured continuous phase sodium nicotinate concentration of the 
formulations 
 CF10 Cf50 E LD 
Calculated 
continuous phase 
concentrationa 
11.18 22.22 21.27 11.11 
Measured 
continuous phase 
concentrationb 
11.03±0.37 26.96±3.31 23.11±0.53 10.6±0.93 
aCalculated concentrations are based upon negligible partition of sodium nicotinate, expressed 
as nicotinic acid, into the dispersed phase structures of the formulations. bMeasured 
concentrations result from ultra-filtration experiments, n=3. Values denote mg/g ± SD 
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Table 6 Chemical composition of received fractions following ultracentrifugation of formulation 
CF10 after evaporation and of a prepared formulation of equal composition 
 Nicotinic 
acid 
Water Phospholipids Mygliol 
812N 
Polysorbate
20 
Summation 
Complete, 
ev. 5.28 48.95 9.82 34.89 7.76 106.70 
Complete, 
sim. 4.75 48.00 9.64 34.09 7.27 103.77 
A, ev. 0.41 3.00 1.74 80.23 1.94 87.32 
A, sim. 1.26 9.23 3.60 83.76 3.98 101.83 
B, ev. 7.47 75.14 6.73 4.57 5.27 99.17 
B, sim. 6.57 75.23 6.37 3.03 6.98 98.17 
C, ev. 7.43 64.75 11.66 4.60 9.94 98.37 
C, sim. 6.86 63.98 12.15 6.97 10.98 100.94 
       
Values denote weight-% of each analysed component of a fraction. The abbreviations ev. and 
sim. indicate the formulation after evaporation and the identical prepared formulation that 
simulates the one after evaporation. The composition of the formulation rests upon the 
remaining water content after evaporation. No ethanol remained in the formulation after 
evaporation. 
 
 
Table 7 Change of electric conductivity of formulation CF10, CF50 and E during evaporation of 
volatile components 
CF10  CF50  E  
Rem. watera El.Cond.b Rem. watera El.Cond.b Rem. watera El.Cond.b 
76.41 1549 37.9 1830 39.53 2360 
25.46 480 25.94 1200 21.82 1800 
19.6 32 14.2 40 14.51 1200 
12.78 8.3 12.09 10 7.78 600 
aRemaining water (weight-%), belectric conductivity (µS/cm) 
 
 
Table 8 Calculated and measured continuous phase sodium nicotinate concentrations of 
formulation LD and CF10 after evaporation to a specific remaining water content 
Formulations Remaining water 
(weight-%) 
Calculated 
continuous phase 
concentrationa (mg/g) 
Measured continuous 
phase concentrationb 
(mg/g) 
LD 63.44 57.63 60.93 
CF10 48.95 102.41 103.05 
aThe concentrations were calculated using Eq. (12). bMeasured concentrations result from 
ultrafiltration experiments 
 
 
Table 9 Intrinsic permeability coefficients calculated with continuous phase drug concentration 
Formulation CF10 LD E Aqueous gela 
Pint 8.56E-08 ±2.18E-08 
9.62E-08 
±2.72E-08 
7.43E-08 
±2.34E-08 
7.87E-08 
±8.53E-09 
Values denote cm/s ± SEM, n=8, an=19 
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E. Appendices 
This chapter contains additional validation procedures, data and analyses to the publications 
that are not jet described. 
E.1 Model Drugs  
The criteria for the selection of the model drugs were similar molecular weight, strongly 
hydrophilic solubility properties and aromatic structure because HPLC-quantification was 
performed UV-spectrophotometrically. 
 
Nicotinic acid  
Nicotinic acid had the function of a hydrophilic, negatively charged model drug and has the 
following structure:  
 
N
OHO
 
MW=123.11 g/mol, pka=4.85 
Sigma (St. Louis, MO, USA) 
 
Within the study formulations, the hydrophilic continuous phase of formulations was adjusted 
to a pH of 7.4 with sodium hydroxide. Hence, this situation yielded complete deprotonation of 
nicotinic acid to sodium nicotinate. 
Benzyltrimethylammonium chloride (BTA-Cl) 
BTA-Cl had the function of a hydrophilic, positively charged model drug and has the following 
structure: 
 
N + Cl
 
MW=185.70 g/mol 
Fluka Chemie Gmbh (Buchs, Switzerland) 
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Caffeine 
Caffeine had the function of a hydrophilic, uncharged model drug and has the following 
structure:  
N
N
N
N
CH3
CH3
CH3
O
O
 
MW=197.19 g/mol 
Sandoz (Basel, Sitzerland) 
 
E.2 Characterisation of the Formulations 
The characterisation of the study formulations CF10, CF50, E and LD included, among other 
methodologies, chemical component analysis of the received fractions following 
ultracentrifugation and NMR-measurements (For composition of the formulations and detailed 
methodology, see chapters D.1 and D.2).  
E.2.1 Phospholipid Content 
Phospholipids were quantified by determination of anorganic phosphate after digestion of the 
phospholpids with a sulphuric / perchloric acid mixture. A spectroscopic method based on the 
formation of a coloured complex of phosphomolybdate with malachite green absorbing at 610 
nm was applied (1).  
 
Table E.2.1 Phospholipid content derived from NAT 8539® calibration curves 
Concentration NAT 8539® 
(µg/ml) Absorption 
Concentration phospholipids 
(weight-%) Accuracy 
Calibration curve 1    
3.72 0.110 65.39 -3.77 
6.197 0.161 63.63 -5.60 
9.3 0.230 64.87 -4.30 
12.39 0.303 66.25 -2.87 
24.8 0.575 66.00 -3.12 
Calibration curve 2       
2.46 0.055 45.33 -24.66 
4.92 0.105 50.33 -19.45 
9.85 0.218 56.13 -13.41 
12.3 0.241 49.94 -19.85 
18.46 0.384 54.71 -14.88 
Calibration curve 3       
2.486 0.064 29.00 -41.67 
4.972 0.124 50.65 -19.11 
9.944 0.253 63.94 -5.27 
12.43 0.322 67.75 -1.30 
24.86 0.621 69.91 0.95 
 
Because of the heterogeneity of the bulk phospholipids NAT 8539®, a NaH2PO4 standard 
solution was used for calibration curves. The valuable absorption range for the method was 
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estimated by calculating phospholipid content of NAT 8539® from several NAT 8539® 
calibration curves. The absorption values given in Table E.2.1 are averages of two separately 
performed chemical digestions of every analytical run. The accuracy rests on the theoretical 
content of phospholipids (totally 69%, including Phosphatidyl choline, Lysophosphatidylcholine, 
Cephalin and Phosphatic acid) that are contained in NAT 8539® according to the manufacturer 
(for definition of the accuracy see E.2.3). On basis of the accuracy values given in Table E.2.1, 
all samples were diluted to obtain an absorption value of at least 0.100 in order to quantify 
phospholipids. 
E.2.2 Quantification of Polysorbate 20 and Triglycerides 
Polysorbate 20 and triglycerides (Mygliol 812N®) were quantified by HPLC following 
saponification and derivatisation with 9-anthryldiazomethane (ADAM) of the lauric acid and 
capric acid, respectively (see chapter D.2) (2). Fig.E.2.1 shows representative chromatograms 
obtdained from (a) blank ADAM, (b) formulation LD, (c) Mygliol 812N® (triglycerides) and (d) 
polysorbate 20. The marked acid peaks 2 and 3 of Fig.E.2.1 were assigned to the specific 
ADAM-esters according to chromatograms received from capric acid and lauric acid, 
respectively (chromatograms not shown). Peak 1 is supposed to result from the caprylic acid 
ADAM-ester. The chromatogram received from formulation LD (Fig.E.2.1 (b)) shows that the 
phospholipids used contained no lauric,- capric,- and caprylic acid or other compounds that 
could interfere with the peaks of the ADAM-esters of these fatty acids. Thus, triglycerides or 
polysorbate 20 may be quantified beside phospholipids. Furthermore, the chromatogram 
received from bulk triglycerides (Fig.E.2.1 (c)) shows no lauric acid peak, although medium 
chain triglycerides may contain up to three percent of lauric acid (3). The capric acid gave 
better results for quantification of triglycerides than the caprylic acid. Hence, triglycerides were 
quantified on basis of capric acid ADAM-esters. However, the chromatogram received from 
polysorbate 20 shows small peaks of caprylic- and capric acid ADAM-esters, in accordance 
with the substance description (4). Thus, the capric acid peaks that were used to quantify the 
triglycerides were corrected by subtraction of the area caused by polysorbate 20 in the sample 
in some cases (this correction was necessary in case of the fractions B of CF10, CF50 and E, 
see chapter D.2 for details).  
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(a) 
(b) 
(c) 
(d) 
 
Figure E.2.1 Chromatograms of (a) blank ADAM, (b) formulation LD, (c) Mygliol 812N® and (d) 
Polysorbate 20. (1) Caprylic acid (C8:0), (2) Capric acid (C10:0), (3) Lauric acid (C12:0) 
 
Furthermore, the time to yield complete saponification of the respective compounds was from 
interest. This time was estimated by measuring the obtained peak areas of a mixture of 
triglycerides and polysorbate 20 (36.3 and 58.8 µg/ml in the final sample for injection, 
respectively) of the ADAM-esters of the fatty acids at different time points after incubation with 
1 
2 
1 
2 
3 
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sodium hydroxide solution (see chapter D.2). The constant peak area after 5 hours of 
saponification (Fig.E.2.2) indicated complete saponification after that time. 
 
 
 
 
 
 
 
 
 
Figure E.2.2 Saponification time of the analysed fatty acids  
E.2.3 Validation Parameters Derived from Chemical Component Analysis 
In addition to chemical component analysis of received fractions following ultracentrifugation 
(see D.1, D.2), the complete formulations were analysed for the respective compound equally 
to test the validity of the applied assays. 
 
Table E.2.2 Measured and true concentrations (C(meas) and C(true), respectively) of respective 
components of the formulations 
Formulation CF50  CF10  LD  E  
 C(true) C(meas) C(true) C(meas) C(true) C(meas) C(true) C(meas) 
Drugs         
NA 1 1.03±0.02 1.00 1.03±0.04 1.00 1.04±0.02 1.00 1.07±0.08 
BTA-Cl 1 1.03±0.02 1.00 1.02±0.03 1.00 1.01±0.03 1.00 1.04±0.03 
Caffeine 1 0.94±0.06 1.00 0.99±0.07 1.00 1.00±0.08 1.00 0.96±0.08 
Bases                 
Water(I) 34.91 35.77±0.38 74.22 76.45±1.99 74.63 75.16±1.76 36.99 36.83±0.79 
Water(II) 34.91 35.30±1.70 74.22 75.63±1.84 74.63 76.05±0.02 36.99 37.91±0.81 
Water(III) 34.91 35.58±0.75 74.22 77.12±1.12 74.63 74.94±1.68 36.99 39.16±3.24 
EtOH(I) 9.95 9.73±2.23 14.77 12.80±0.48 14.98 12.88±0.74 10.00 9.14±0.72 
EtOH(II) 9.95 8.01±0.47 14.77 13.69±2.08 14.98 12.96±1.04 10.00 9.01±1.14 
EtOH(III) 9.95 8.45±0.81 14.77 13.04±0.89 14.98 12.88±0.76 10.00 8.43±0.24 
PL(I) 10.04 9.38±0.98 1.81 1.76±0.13 9.29 8.70±0.81     
Mygliol(I) 36.01 38.54±0.98 6.78 7.13±0.46   48.00 48.62±1.19 
PS 20(I) 8.00 7.20±0.50 1.36 1.56±0.25   4.01 3.76±0.51 
NA denotes sodium nicotinate, expressed as nicotinic acid, BTA-Cl denotes benzyltrimethylammonium 
chloride, PL are phsopholipids, Mygliol triglycerides and PS 20 denotes polysorbate 20. The index (I), 
(II) and (III) behind the respective components distinguishes between analyzed data obtained from the 
same formulation containing NA, BTA-Cl or caffeine as model drug, respectively. Data denote weight-
%±SD, n=3-6 
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Table E.2.2 compares the analysed amounts of assayed components with the true values 
given by the respective formulation composition. On basis of these data, the accuracy (AC), 
the precision (P) and the recovery (R) of the respective analytical method was calculated as: 
 
    100⋅−=
TV
TVMAC    (E1) 
 
    100⋅=
M
SDP     (E2) 
 
    100⋅=
TV
MR     (E3) 
 
where, M is the mean of the analysed individual component, TV is the true value and SD is the 
standard deviation (5).  
 
Table E.2.3 Validation parameters derived from chemical component analysis of the complete 
formulations 
Formulation CF50   CF10   LD   E   
 AC P R AC P R AC P R AC P R 
Drugs             
NA 3.22 2.10 103.33 3.06 3.98 103.15 3.92 1.61 104.08 6.29 7.34 106.71 
BTA-Cl 3.17 1.54 103.27 2.16 3.08 102.21 0.95 2.94 100.95 4.25 2.85 104.43 
Coffein -5.89 6.15 94.44 -1.20 7.45 98.81 -0.06 7.63 99.94 -4.15 8.11 96.02 
Bases             
Water(I) 2.41 1.06 102.46 2.91 2.60 103.00 0.71 2.35 100.71 -0.45 2.14 99.55 
Water(II) 1.11 4.83 101.13 1.86 2.44 101.89 1.87 0.03 101.91 2.41 2.14 102.47 
Water(III) 1.88 2.09 101.92 3.76 1.46 103.90 0.42 2.24 100.42 5.53 8.27 105.85 
EtOH(I) -2.31 22.97 97.74 -15.41 3.74 86.65 -16.35 5.76 85.95 -9.38 7.83 91.42 
EtOH(II) -24.27 5.87 80.47 -7.92 15.23 92.67 -15.59 8.04 86.52 -10.99 12.62 90.10 
EtOH(III) -17.71 9.59 84.96 -13.27 6.80 88.29 -16.33 5.91 85.96 -18.58 2.79 84.33 
PL(I) -7.05 10.40 93.41 -3.04 7.26 97.05 -6.78 9.27 93.65       
Mygliol(I) 6.56 2.53 107.02 4.80 6.42 105.05       1.29 2.45 101.30 
PS 20(I) -11.07 7.00 90.03 12.92 15.91 114.84       -6.57 13.44 93.83 
NA denotes sodium nicotinate, expressed as nicotinic acid, BTA-Cl denotes benzyltrimethylammonium 
chloride, PL are phsopholipids, Mygliol triglycerides and PS 20 denotes polysorbate 20. The index (I), 
(II) and (III) behind the respective components distinguishes between analysed data obtained from the 
same formulation containing NA, BTA-Cl or caffeine as model drug 
 
A recovery ± 20 % and deviation of less than ±20 for the accuracy and the precision, 
respectively, was tolerated. Hence, all methods were valuable to analyze the respective 
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component within the formulation matrix (Table E.2.3). The detected higher deviations for the 
ethanol were attributed to its volatility. 
E.2.4 NMR Diffusion Experiments 
In order to determine self-diffusion coefficients of sodium nicotinate and benzene, NMR 
diffusion experiments were performed (see chapter D.1) (6). Fig.E.2.3 shows two NMR spectra 
obtained from the aromatic protons of sodium nicotinate. Fig.E.2.3 (a) gives a typical spectrum, 
with signal peaks of high resolution, as obtained from sodium nicotinate within all study 
formulations, except the emulsion E, where broad signal peaks were observed. This spectrum 
is given in Fig.E.2.3 (b). 
 
 
 
Figure E.2.3 NMR spectra of sodium nicotinate obtained from (a) the drug within the isolated 
microemulsion of CF50 and (b) from formulation E 
 
The reason for these broad signal peaks was not further invesitigated. Ultrafiltration 
experiments, however, excluded an association of sodium nicotinate with dispersed structures, 
which could be a possible explanation for this observation (see chapter D.1).  
Diffusion experiments were performed by varying the gradient strength while keeping the 
diffusion times and gradient lengths constant. Self-diffusion coefficients were fitted from the 
intensity decrease of a NMR signal of interest using Eq. (E4) (7): 
 
10000)
3
()2(
0
2
⋅−∆⋅⋅⋅⋅⋅⋅−
⋅=
δ
piδ GHD
g eII  (E4) 
 
where, Ig and I0 are the signal intensities in the presence and absence of magnetic field 
gradient pulses with the amplitude G and the duration δ. ∆ Denotes the experimental diffusion 
time, D the diffusion coefficient and Н is given with 4258 Hz/G and depends on the 
gyromagnetic constant for 1H. Fig. E.2.4 shows a typical fit. 
 
(a) 
(b) 
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Figure E.2.4 Example of a fit to determine self-diffusion coefficients using Eq. (E4)  
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E.3 Permeation Experiments 
This chapter contains validation procedures and additional experiments to the permeation 
experiments (see chapters D.1 and D.2) that are not jet described. 
E.3.1 Determination of the Effective Transport Area 
The custom-made Franz-type diffusion cells used in this work consist of an upper and a lower 
glass-compartment (Fig.E.3.1). For all permeation experiments, the skin was placed between 
these two compartments, stratum corneum side up, followed by application of the donor 
formulation. For interpretation of drug flux according to Fick`s first diffusion law, information 
about the effective transport area is essential (see chapter C.4). The area of the upper and 
lower compartment of the applied diffusion cells (Au and Al in Fig.E.3.1, respectively) was not 
identical (see Table E.3.1).  
 
 
Figure E.3.1 Diffusion cells, upper (I) and lower (II) compartment and upper and lower skin-contact 
area, Au and Al, respectively 
 
Thus, several permeation experiments with identical purely aqueous sodium nicotinate 
solutions as donor vehicle were carried out occlusively to estimate the relevant diffusion area. 
 
Table E.3.1 Permeability coefficients calculated with the upper (Pu) and lower (Pl) areas of the diffusion 
cell compartments  
 Cell1 Cell2 Cell3 Cell4   
Upper Area 2.125 1.767 1.86 1.72   
Lower Area 2.99 3.05 3.24 4.05   
Experiment1     Average RelSD  
Pu 2.3E-07 3.69E-07 3.2E-07 3.92E-07 3.27E-07 21.8 
Pl 1.64E-07 2.14E-07 1.84E-07 1.66E-07 1.82E-07 12.7 
Experiment2       
Pu 2.69E-07 3.28E-07 3.58E-07 4.25E-07 3.45E-07 18.8 
Pl 1.91E-07 1.9E-07 2.06E-07 1.8E-07 1.92E-07 5.47 
Pu and Pl denote permeability coefficients (cm/s) calculated with the skin contact area of the upper and 
lower cell compartment, respectively. RelSD is the relative standard deviation (%). Areas are given in 
cm2. Two experiments were performed. 
 
(I) 
(II) Au 
Al 
Au Al 
(I) 
(II) 
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Table E.3.1 shows that the permeability coefficients calculated with the area of the lower cell 
compartment gave a smaller variation, indicating that this area represents the effective 
diffusion area more precisely. Hence, the areas of the lower cell compartments were used for 
the interpretation of all permeation experiments in this work. 
E.3.2 Validity Testing of TEWL Measurements  
Skin integrity was tested prior to every permeation experiment by measuring the 
transepidermal water loss (TEWL) across the skin. The validity of this method was evaluated 
by comparing TEWL-values obtained from intact skin with TEWL data measured across 
stripped skin after an equilibration time of about 4 hours, experimental conditions according to 
the permeation experiments (see chapters D.1, D.2). Stripped skin reportedly looses its barrier 
properties and, hence, TEWL values will increase (8). 
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Figure E.3.2 Transepidermal water loss across excised full thickness pig ear skin (n=112) and across 
excised stripped pig ear skin (n=33) Error bars denote standard error of means (SEM) 
 
Fig.E 3.2 clearly demonstrates that the experimental in-vitro conditions used in this work allow 
distinguishing between intact and damaged skin using the technique of transepidermal water 
loss measurements. 
E.3.3 Formulation Dosage Facilitating Alterations due to Evaporation 
To investigate sodium nicotinate permeation from non-occlusively applied formulations (see 
chapter D.2), evaluation of an appropriate dosage of formulations was required. On the one 
hand, the applied amount had to be small enough to enable alterations due to loss of volatile 
components during the investigated time, but on the other hand, the remaining amount of 
formulation had to be sufficient enough facilitating physicochemical characterisations at the 
end of experiments. For that reason, different amounts of formulation CF10 were applied on 
pig ear skin, equal conditions to the permeation experiments (see chapter D.2). After 54 hours, 
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the formulations were removed from the skin surface and analysed for remaining water and 
ethanol.  
 
Table E.3.2 Remaining volatile components after 54 hours of application 
Formulation applieda Remainig water (%) Remaining ethanol (%) 
100 mg/cm2 Not removable -- 
300 mg/cm2 34.58 0 
350 mg/cm2 53.66 0 
400 mg/cm2 45.51 0 
500 mg/cm2 72.8 0 
aFormulation CF10, initially containing 90 weight-% of volatile phase 
 
Table E.3.2 shows that 100 mg/cm2 applied formulation is less to make a collection possible 
after the duration of an experiment, while a dosage of 500 mg/cm2 is too large to cause major 
alterations of the formulation composition due to loss of volatile components. Thus, 300 
mg/cm2 was identified as valuable formulation dosage for the project published in chapter D.2.  
E.3.4 Distribution Experiments between Stratum Corneum and Formulations 
The method for the determination of drug distribution coefficients between the stratum 
corneum (SC) and continuous phase of formulations was developed (see chapter D.1). The 
following validation procedures were performed. (I) The time of sonification to obtain complete 
drug extraction from the SC was investigated, (II) the recovery of the respective drug from SC 
tissue was from interest and (III) the concentration dependency of formulation concentration on 
drug concentration within the stratum corneum was studied.  
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Figure E.3.3 Theoretical drug concentrations of SC (CSC(mg/g)) as a function of sonification time (s). 
Results were obtained from equilibrated SC tissue with donor solutions containing 1 weight-% of drug in 
aqueous/ethanolic buffer solution pH 7.4 
 
Fig.E.3.3 demonstrates that after 10 seconds of sonification, all drug was extracted from the 
SC tissue, independently of the used drug. However, without sonification, considerable amount 
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of drug would remain in the SC, as attested by the extracted amount without sonification. For 
experimental details and HPLC assays see chapter D.1. 
 
Table E.3.3 Drug retention within the SC 
 Sodium nicotinate BTA-Cl Caffeine 
Retention (%)/ 
mg SC± SD 
1.82±0.57 2.79±0.73 2.54±1.60 
 
Because the SC constitutes a complex, heterogeneous matrix (see chapter C.1.2), binding and 
absorption of the drugs to this tissue may not be automatically excluded. Hence, the recovery 
of the drugs from SC was investigated. For that purpose, 10 µl of aqueous drug solution (1 
weight-%) was added to the surface of accurately weighted pieces of SC. Then the drug 
solution was allowed to evaporate over night, followed by drug extraction as described in 
chapter D.1. The results are expressed as drug retention (in % of complete amount of drug) / 
mg SC (Table E.3.3). However, blank runs, where SC was replaced by filter paper, gave 
similar results, indicating that drug binding to the SC may be neglected for the tested 
hydrophilic model drugs.  
To make sure that the SC is not saturated with the drugs and to confirm the dependency of 
formulation concentration on drug concentration within SC, distribution coefficients between 
SC and solutions (17 % ethanol in aqueous buffer pH 7.4) of different drug concentrations 
were determined. The range of these concentrations was chosen in order to include 
continuous phase drug concentrations of the study-formulations E, CF50, LD and E. 
 
 
 
Figure E.3.4 Dependence of drug concentration of stratum corneum (CSC(mg/g)) on donor drug 
concentration (CDonor(mg/g)) 
 
Fig.E.3.4 clearly demonstrates linearity between SC drug concentration and donor drug 
concentration, according to theory. The unequal values for the different drugs further indicate 
that the measured concentrations were not due to remaining formulation on the SC. This was 
evidenced with additional experiments that were performed by covering hydrated SC with drug 
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containing formulation CF50. This formulation was removed and the SC pieces were tested for 
drug concentration. No drug was found.  
E.3.5. Sodium Nicotinate Liberation Experiments  
Sodium nicotinate liberation experiments from the study formulations across a porous matrix 
were carried out in order to test the validity of the continuous phase drug concentration 
concept additionally to the caffeine permeation experiments across a silicon membrane (see 
chapter D.1). A setup of two layers of HDS Aqueous Polymer Hydrogel (Hydrogel Design 
System, Langhorn, USA), sandwiched between two shields of cellulose filter paper, was found 
to be an appropriate matrix for that purpose (Fig.E.3.5). 
 
 
 
Figure E.3.5 Cumulated liberated sodium nicotinate amount from the study-formulations 
 
The sodium nicotinate gave a linear liberation profile with the square root of time at later time 
points of the experiment. This liberation pattern may be described by: 
 
pi
tDCQ tot
⋅
⋅⋅= 2    (E5) 
 
where, Q is the amount of drug released to the sink per unit area, Ctot is the overall dissolved 
drug concentration of the formulation, t the time and D the diffusion coefficient of drug within 
the formulation (9). Liberation constants L were derived from Eq. (E5) from the slope of the 
linear portion of the liberation curve (Fig.E.3.5). According to the continuous phase drug 
concentration concept (see chapters D.1, D.2), these constants were corrected by the 
continuous phase drug concentration and gave Lk1. However, Eq. (E5) indicates that a further 
correction is necessary, because diffusion of drug within the formulations may not be 
neglected in the situation of negligible diffusional resistance of the membrane. Hence, the 
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liberation constants were additionally corrected by dividing through the square root of sodium 
nicotinate self diffusion coefficients derived from NMR diffusion experiments (see chapter D.1). 
These different liberation constants are given in Table E.3.4. 
 
Table E.3.4 Liberation constants of sodium nicotinate  
 L (µg/cm2/SQRT(s)) Lk1 (cm/SQRT(s)) Lk2 
CF10 11.72 0.0011 5053 
LD 8.25 0.00074 5018 
Gel 13.45 0.0013 5652 
E 10.93 0.00051 3256 
CF50 9.36 0.00042 2853 
L denotes the liberation constants, where the superscript k1 denotes a correction by dividing through 
continuous phase drug concentrations (µg/cm3), and k2 a further correction by dividing through the 
square root of the diffusion coefficient (cm/Sqrt(s))of drug within the formulation. 
 
This correction yielded comparable liberation constants Lk2 for LD, CF10 and the gel, indicating 
the validity of the continuous phase drug concentration concept. Lk2  values for E and CF50 
were also comparable, but different to the values obtained from CF10, LD and E. This may be 
due to diffusion of water from the receptor to the donator compartment of the diffusion cells, 
decreasing the concentration directly above the membrane.  
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